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I INTRODUCTION 
Coxiella burnetii (Cb) is the causative agent of Q fever in humans and animals and is 
classified as category B biological agent [1]. Q fever is an endemic zoonotic disease 
worldwide, except for New Zealand [2]. The pathogen is a Gram-negative, obligate 
intracellular bacterium and is able to infect various host species [3, 4]. In humans, 
clinical findings vary from asymptomatic, mild or acute symptoms (self-limiting flu, 
atypical pneumonia, hepatitis) to chronic life-long and life-threatening outcomes 
(endocarditis, vascular infections) [3, 5-7]. In animals, no clinical signs are seen usually 
and Cb infections are often subclinical. However, main clinical signs in domestic 
ruminants are reproductive disorders such as (late) abortion or weak offspring [8-10]. 
Cattle, sheep and goats are considered as main reservoirs for the Q fever agent and 
small ruminants are the most potential source of infection for humans [8, 10-12]. The 
bacteria are excreted in high numbers with birth products during parturition as well as 
with several body fluids (vaginal mucus, milk, feces) and lead to contamination of the 
environment [11, 13]. Inhalation of contaminated aerosols is the most common infection 
route in humans [14-16]. Several factors e.g. environmental conditions (wind, dry areas) 
facilitate spreading and dissemination of Cb and are associated with a higher infection 
risk for humans [17, 18]. 
In African countries, only few studies are available of Cb-specific antibody prevalences 
in humans and animals and little is known about the disease, diagnosis, animal disease 
control and public health countermeasures. Very limited information is available about 
the epidemiology of Cb in humans and animals, although African countries like Egypt 
may provide good conditions for Cb transmission: environmental factors, increasing 
livestock production and constantly growing human population, frequent animal 
movements and preserved traditions. Awareness rising measures in animal keepers, 
veterinarians and physicians are necessary to implement the “One Health” approach in 
African countries ensuring animal welfare and public health and decreasing the 
socioeconomic burden in agricultural countries. 
Therefore, this nationwide present survey was carried out to describe the 
seroepidemiological situation of Cb-specific antibodies in ruminants and camels in 
Egypt (except the Sinai). Serum samples were investigated using a commercially 
available enzyme linked immunosorbent assay (IDEXX CHEKIT Q fever Antibody 
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ELISA Test Kit). Milk investigations were done independently of the study in 
consideration of the still ongoing debate about the unresolved correlation of antibodies 
found in blood and milk. Prevalence data of Cb-specific antibodies in milk of any farm 
animal species have not been reported in Egypt until today. The elucidation of the 
correlation of the results to specific risk factors may provide a baseline data for support 
and improvement of public health countermeasures and animal welfare. The research 
results may also be used to tailor further epidemiologically studies especially in 
humans. 
 
3 
Literature Review 
 
 
 
II REVIEW OF LITERATURE 
1 History of Coxiella burnetii 
Q (query) fever was first described in 1937 by E. H. Derrick studying an outbreak of an 
unknown febrile illness among abattoir workers in Queensland, Australia in 1935 [19]. 
Experimental infection of guinea pigs but no visualization of the pathogen raised the 
later reversed assumption that the disease causing agent was an unknown virus [19, 20]. 
In 1938 F. M. Burnet and M. Freeman were able to reproduce the characteristic febrile 
disease in guinea pigs, using infected tissues provided by Derrick. They discovered 
Rickettsia-like bacteria in smears of spleen tissue from infected mice [20]. At the same 
time, G. Davis discovered Coxiella as infectious agent by accident during a field study 
on Rocky Mountain spotted fever (1935). He collected ticks near the Nine Mile Creek 
in Montana, USA. These ticks were fed on guinea pigs and induced a febrile illness that 
did not resemble Rocky Mountain spotted fever [21]. Further studies together with H. 
R. Cox on the isolation and cultivation of the “Nine Mile Agent” led to the decision that 
the agent had bacterial and viral characteristics [21-23]. Cox succeeded in cultivating 
the “Nine Mile Agent” in embryonated hen eggs, in which he observed Rickettsia-like 
bacteria in large numbers within the yolk sac membrane tissue [21, 24]. R. E. Dyer 
doubted Cox’s culturing method due to his own failure in this matter and visited Cox to 
work together with him in his laboratory. Dyer contracted a laboratory infection and 
showed symptoms of Q fever after his return. This suggested that the “Nine Mile 
Agent” and the Q fever pathogen discovered by Derrick were the same agent. The 
assumption was validated in cross protection studies by Dyer in 1939 [21, 25]. 
In 1948 the agent was named as “Coxiella burnetii” to honor the researchers 
F. M. Burnet and H. R. Cox characterizing the Q fever bacterium nearly simultaneously 
[26]. In recent years, Cb was reclassified several times based on modern taxonomy 
studies. 
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2 Etiology and Pathogenesis 
2.1 Taxonomy 
From the discovery of Coxiella burnetii up to the 1990s the agent was often reclassified 
due to advanced phylogenic analysis methods. The original name of the Q fever 
pathogen was “Rickettsia burnetii” because of similar characteristics to Rickettsia 
organisms e.g. having a reservoir in ticks and being an obligate intracellular small 
coccoid rod. Until the 1990s Cb was classified as an α-Proteobacterium, in the order 
Rickettsiales, family Rickettsiaceae with the tribes Rickettsieae (with the genus 
Coxiella), Wolbachieae and Ehrlichiae. Further analysis of six selected species out of 
the family Rickettsiaceae based on the 16S rRNA gene sequence resulted in the 
reclassification of Cb as member of the γ-subdivision of the Proteobacteria. This survey 
also revealed that the phylogenetic origin of Cb is closer to the genus Legionella than to 
the genus Rickettsia. Nowadays, Legionella pneumophila is known as the closest 
relative of Cb [27]. This finding was also confirmed by Stein et al. comparing five 
human Cb isolates and the Cb Nine Mile tick strain showing a 16S rRNA gene sequence 
identity of more than 99% [28]. 
At present, Coxiella is phylogenetically classified within the phylum of the 
Proteobacteria, class γ-Proteobacteria, order Legionellales, family Coxiellaceae and 
genus Coxiella with a single species C. burnetii (Fig. 1). With the recent description of 
Coxiella cheraxi sp. nov. and the discovery of Coxiella-like tick endosymbionts the 
single species status of the genus Coxiella has to be re-evaluated [14, 29, 30]. It was 
suggested that the Coxiella-like endosymbionts represent the ancestors of Cb with less 
or nearly none virulence factors making Cb capable of successful infection of 
vertebrates [31]. 
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Figure 1. Current taxonomic classification Coxiella burnetii. 
Created by P. Thomas (IBIZ, FLI). 
Phylogenetic tree based on 16S rRNA gene sequences demonstrating the classification 
of Coxiella burnetii and Coxiella-like strains into the γ-Proteobacteria and showing the 
close relatedness of Cb and Coxiella-like organisms. 
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2.2 Bacteriology 
2.2.1 Morphology 
Coxiella burnetii is an obligate intracellular Gram-negative bacterium. It is a small, 
non-motile and pleomorphic coccobacillus with a width of 0.2-0.4 µm and a length of 
0.4-1.0 µm [3, 4]. It has a typical Gram-negative cell wall with an inner and outer 
membrane, a periplasmic space and lipopolysaccharides (LPS) as major component of 
the outer leaflet of the outer membrane [4]. The bacteria stain Gram-variable and 
therefor Gimenez staining is the most used staining method [32]. 
Cb has a generation time of 8-12 h and undergoes developmental differentiation with 
two morphological distinct cell forms during its intracellular life cycle: a small cell 
variant (SCV) and a large cell variant (LCV; Fig. 2) [33, 34]. These morphotypes are 
distinguished by their ultrastructure and cell wall content, metabolic capabilities, protein 
compositions and physical resistances [33]. LCV have a size of 1 µm in diameter with a 
thin cell wall and an irregular shape. A dispersed nucleoid with a more scattered 
chromosome, a filamentous nucleoid region and granular or filamentous cytoplasm are 
characteristics of the LCV. Contrary, SCVs are 0.2-0.5 µm in length and are typically 
rod-shaped with a thick wall, characteristic condensed chromatin and an arrangement of 
intracytoplasmic membranes [4, 33]. Additionally, Cb displays two phase variations 
with different LPS length, designated as i.e. Phase I (smooth LPS) and Phase II (rough 
LPS) [35, 36]. 
 
Figure 2. The two different morphotypes of Coxiella burnetii. 
Cited from Coleman et al. (Coleman et al. 2004). 
Small cell variant and large cell variant in cell culture (Vero cell) on day 6 post infection.  
LCV 
SCV 
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2.2.2 Genome and Genotyping 
Cb Nine Mile Phase I (RSA 493) was the first isolate to be sequenced and the genome 
was published in 2003. Compared to other obligate intracellular bacteria Cb isolates 
have a relatively large circular genome of approximately 2 Mbp [37-39]. Additionally, 
each isolate harbor either one of five plasmids (QpH1, QpRS, QpDV, QpDG or a no 
further characterized plasmid from a Chinese isolate). They can also be free of plasmids 
with chromosomal integrated plasmid related sequences. Plasmid size ranges from 36 to 
56 kbp except for chromosomal integrated homologous sequences with a size of 16 kbp 
[37, 39, 40]. Numerous pseudogenes indicate that genome reduction is an ongoing 
process reflecting the still ongoing adaptation to an obligate intracellular lifestyle [38, 
41, 42]. Genetic elements such as three degenerate transposons and 29 insertion 
sequences (IS) are present [38, 43, 44]. These elements are transferred horizontally 
which is uncommon for obligate intracellular bacteria [43, 44]. The IS1111 transposase 
element is present in multiple copies and the copy numbers vary tremendously in 
different strains. Hence, this sequence is used in general for detection of Cb using 
polymerase chain reaction due to high sensitivity and specificity [45, 46]. Nevertheless, 
this method has to be re-evaluated since both Cb and Coxiella-like tick endosymbionts 
harbor this element. 
Restriction fragment length polymorphism (RFLP) was used for early comprehensive 
genetic discrimination of Cb isolates from different species and geographical origin. Six 
genomic groups were described based on the correlation of plasmid content and 
manifestation of Q fever especially in humans [47, 48]. Some plasmid types have 
homologous regions [49, 50]. Consequently, the virulence of a Cb strain plays an 
important role. However, pathogenicity and disease outcome might be independent of 
plasmid type and depends also on predispositional factors of the host [51]. 
Genotyping of Cb for epidemiological investigations experienced a remarkable 
revolution due to several Q fever outbreaks in humans in the last decade. Today, newer 
genotyping methods are multispacer analysis, multiple variable numbers of tandem 
repeats analysis (MLVA), single nucleotide polymorphism analysis (SNP) and 
multispacer sequence typing (MST) analysis. Usually, a combination of MLVA, MST 
and SNP is currently used [52-55]. 
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2.2.3 Developmental Life Cycle 
Cb is not able to replicate outside host cells naturally [33, 34]. Despite the long 
generation time of up to 12 h replication follows a typical bacterial growth curve with a 
lag phase, exponential growth (log phase) and stationary phase [34]. Interestingly, Cb 
displays a biphasic developmental cycle with a replicative (LCV) and a spore-like 
dormant (SCV) cell form (Fig. 3) [4, 56]. During growth, these cell forms show 
characteristic appearance, gene expression, regulatory and structural components [34, 
56-58]. Similarities with this particular life cycle and replication process were seen in 
other obligate intracellular bacteria e.g. Chlamydia spp. [33]. 
After internalization, the SCV reside in a parasitophorous vacuole [34]. Within the first 
two days during the lag phase the metabolic quiescent SCV differentiate into the 
replicative LCV form. Appearance of LCV indicates transition into the exponential 
phase with an increased transcriptional activity in the target cells. After approximately 
six days post infection with the onset of the stationary phase, LCVs start the 
morphological differentiation back into SCVs [34, 56]. The number of SCVs increases 
the following two days [34]. During this differentiation electron-dense, polar bodies can 
be observed in the LCVs [4, 33, 38, 57]. Differentiation into SCVs ensures survival 
within the environment [34]. LCVs are known as the replicative intracellular form of 
Cb. These cells are very unstable and fragile outside the host cell [33, 34]. Considering 
the high tenacity and resistance of the SCVs to environmental conditions and against 
chemical and physical factors, it is not surprising, that these are considered as 
“spore-like” extracellular survival forms. Resistance of the Q fever pathogen against 
heat, desiccation, pressure, high or low pH, UV rays, disinfectants and chemical agents 
has been demonstrated [4, 33, 59-61]. The main infectious stage of Cb is the SCV. 
Nevertheless, the infectious potential of LCVs should not be underestimated [33]. 
Therefore, the risk of infection for humans and animals is increased by remaining Cb in 
the environment. 
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Figure 3. Proposed biphasic developmental cycle of Coxiella burnetii. 
Cited and modified from Minnick et al. (Minnick et al. 2012). 
SCV enters the host cell (e.g. alveolar macrophage) passively by phagocytosis. Acid 
activation of the SCV (due to the acidic environment in the Coxiella-containing 
vacuole) allows morphogenesis to LCV and subsequently replication. Morphological 
differentiation to SCV is initialized at least in the early stationary phase before they will 
be released from the host cell. 
 
2.2.4 Intracellular Niche 
A crucial step in the lifecycle of Cb is the establishment of an intracellular niche within 
the host cell. This niche is unique among intracellular bacteria [62, 63]. Other bacteria 
normally avoid the microbial degradative environment of this “niche”, which shows 
characteristics of a terminal phagolysosome. 
Natural transmission of Cb occurs mainly through inhalation of contaminated aerosols 
[3, 64]. Alveolar macrophages and monocytes are known as primary target cells [65]. 
After uptake via pathogen-induced phagocytosis, SCV resides in a parasitophorous 
vacuole, the so called Coxiella-containing vacuole (CCV) [34]. This CCV passes 
through the endocytic cascade fusing with vesicles of the endosomal and autophagic 
pathway [62, 66]. The CCV is highly fusogenic and finally fuses with lysosomal 
vesicles obtaining characteristics of a terminal phagolysosome such as an approximate 
pH value of 5 and degradative enzymes e.g. acid hydrolases [33, 62, 66, 67]. The acidic 
environment (pH ~ 5) triggers the differentiation of the SCV into the LCV, a 
mechanism termed as acid activation [33, 68, 69]. This acidification process also 
SCV 
LCV 
Lysosome 
Phagosome 
Coxiella-containing vacuole 
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enables active transport of nutrients and generation of ATP due to a proton motive force 
(PMF) driven by the pH gradient between the bacterial neutral cytoplasm and the acidic 
vacuolar environment [68, 70-73]. 
The terminal CCV can occupy almost the entire cytoplasm of the host cell. It is 
interesting, that this is not affecting the host cell’s viability [74, 75]. This underlines the 
assumption of a minimal cytopathic effect of Cb. Further, it is assumed that infected 
eukaryotic cells are not actively lysed by Cb due to missing membranolytic exit systems 
as known for Chlamydia trachomatis [33]. It has been shown that Cb inhibits apoptosis 
of infected cells [76-78]. 
Evolutionary adaptation of Cb was necessary to ensure survival within the harsh 
environment within its unique niche. Therefore, Cb developed specific features. The 
genome of Cb is fitted with an unusual high number of genes encoding for basic 
proteins. These basic proteins with an isoelectric point (pI) value of ~8.25 buffer the 
excess of protons entering from the acidic environment [38]. Additionally, various types 
of secretion systems such as exchangers for protons and transporters for osmoprotection 
are expressed [38]. Especially the type IV secretion system (T4SS) is a noticeable 
virulence factor of Cb as it is involved in the stability and fusogenicity of the CCV and 
the inhibition of host cell apoptosis [79-81]. It has been shown that the Nine Mile 
isolate has over a quarter more drug-efflux systems than other γ-Proteobacteria [38]. 
This fact in combination with the acidic environment in the CCV makes a protracted 
therapeutic approach with antibiotics due to limited antibiotic effects. 
 
2.2.5 Phase Variation 
Cb displays antigenic variation, Phase I and Phase II. This phase variation refers to the 
length and complexity of lipopolysaccharides in the outer leaflet of the outer membrane. 
The virulent Phase I (PhI) bacteria may be isolated from infected hosts like humans, 
animals and ticks. Whereas the Phase II (PhII) avirulent form of Cb may be isolated 
from immune-incompetent hosts e.g. embryonated hen eggs after repeatedly passaging 
of PhI bacteria [35, 36]. The shift from virulent to an avirulent Cb population goes 
along with deletions in the chromosomal DNA finally resulting in, for example, the 
irreversible truncation of the LPS chain [36, 82]. Members of the Enterobacteriaceae 
family show a similar “smooth” and “rough” variation [35, 36]. 
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LPS is considered as a virulence factor of Cb. Until today, chemical composition and 
structure of the LPS has not been completely resolved. Furthermore, it has to be 
mentioned that LPS analyses are mainly described for Nine Mile I and II strains only. 
PhI bacteria express a full length, smooth LPS. It consists of a lipophilic membrane 
anchor (lipid A) linked to a core oligosaccharide and an O-specific polysaccharide 
(O-PS) chain (Fig. 4). The O-PS chain is a heteropolymer and contains different sugars 
like virenose (Vir, 6-deoxy-3-C-methylglucose) and dihydrohydroxystreptose (Strep, 3-
C-(hydroxymethyl)-L-lyxose) [82-85]. These unusual sugars are unique biomarkers as 
these are absent on the surface of any other enterobacterial species [84, 85]. The LPS of 
the avirulent form is severely truncated and resembles a deep, rough LPS chemotype. 
Major differences to the virulent form are the absence of the O-PS and of several sugar 
residues in the core oligosaccharide [82, 86]. 
LPS plays an important role during the host-pathogen-interactions by contributing to the 
immunogenicity and pathogenicity of Cb. Additionally, they are associated with evasion 
of specific immune defense mechanisms like complement-mediated killing and play a 
major role during phagocytosis [87-91]. The full length, smooth LPS of PhI bacteria has 
a low endotoxic potency and toll-like receptor 4 (TLR4) antagonistic properties, 
although it is considered a specific virulence factor of Cb [92, 93]. 
In immune competent hosts, PhII bacteria are eliminated rapidly. However, clinical 
signs such as splenomegaly may be seen in severe combined immunodeficiency (SCID) 
mice to a certain extent [94-96]. Interestingly, various PhII bacteria of Cb are known, 
differing in the surface (protein composition, charge, cell density) [97-100]. 
 
 
 
 
 
Figure 4. Schematic structural arrangement of the lipopolysaccharide of Phase I 
Coxiella burnetii. 
The three units in the LPS consist of specific sugar residues in various number and 
sequence. These units may be seen in Gram-negative bacteria in general. 
  
O-PS Chain Lipid A 
Core Region 
(Outer/Inner) 
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3 Epidemiology 
3.1 Host Range, Reservoirs and Vectors 
Q fever is a zoonosis, more precisely a zooanthroponosis. In consequence, 
Coxiella burnetii is transmitted from animals to humans. Human-to-human infections 
may be exceptional whereas animal-to-animal transmission is common. 
Host range of Cb is impressively various and wide. Wild and domestic mammals are the 
main target hosts but also non-mammalian animals can carry the agent. Domestic 
ruminants like cattle, sheep and goats play an important role for the dissemination of 
Cb. They are considered the main reservoirs for human infections as shown during a 
nationwide Q fever outbreak in the Netherlands (2007-2010) and annually small scale 
outbreaks in Germany [12, 101-103]. The role of camels is unknown regarding bacterial 
shedding and risk for human infection, although DNA of Cb was demonstrated in 
several excretions [104]. Cb-specific antibodies or DNA was also found in cats, dogs, 
pigs and horses [105-110]. Wildlife animals like non-human primates, rodents and big 
game as well as reptiles, amphibians, fish and birds are described as further hosts for Cb 
[111-114]. C. cheraxi sp. nov. was isolated from a freshwater crayfish [30]. The exact 
role of ectoparasites like ticks or other hematophagous arthropods (fleas, mites, lice) as 
vectors in the transmission of Q fever is still under debate although Cb may be detected 
in arthropods worldwide [14, 25, 115-117]. Until now, Cb was detected in more than 40 
tick species [118]. Bacteria were found in their gut, hemolymph and in high numbers in 
their feces.[23, 119-121]. In experimental settings it is possible to infect ticks and 
demonstrate transstadial and transovarian transmission of Cb [120, 122]. It seems like 
they do play a key role in the transmission of Cb between wildlife and humans e.g. in 
Spain, although it has not been proven yet [123]. Nevertheless, the reported prevalence 
in ticks of Cb (up to 10%) has to be reconsidered carefully, since several 
Coxiella-like endosymbionts have been described [124-126]. These bacteria are 
genetically highly similar to Cb and harbor the same multi-copy IS1111 element used 
for PCR detection [127, 128]. Coxiella-like bacteria are also widespread and common in 
ticks [125, 126, 129]. 
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3.2 Global Distribution 
Q fever is present worldwide, except New Zealand [2, 113, 130]. This zoonotic febrile 
disease is endemic due to the resistance of Cb, its spreading ways and the various 
susceptible hosts. Q fever outbreaks are reported for many countries worldwide such as 
Egypt, Germany, the Netherlands, Switzerland or Australia [12, 102, 131-133]. Q fever 
seroprevalence studies are available from nearly all northern, western, central, eastern 
and southern African countries [61, 134-136]. Nevertheless, only few surveys were 
conducted with random sampling or correlated prevalence in human and animal 
populations [136]. 
The seroprevalences in human surveys conducted in Africa vary strongly as seen in a 
study on data of seven African countries (1-37%) and is reported to be 10% in children 
in Niger [133, 134, 137-139]. Tissot-Dupont et al. assumed, that there might exist a 
correlation between high seroprevalences in humans in countries with developed 
livestock industries as demonstrated in data of West Africa, e.g. in Mali with 24%, 
where stock breeding is common [134]. Comparison of prevalence surveys from 
Mediterranean southern European countries to those of northern African countries 
showed similar results and it is speculated that epidemiological characteristics regarding 
Q fever transmission are more similar in both areas [134]. Similar findings in humans 
are not reported for Egypt [134, 136].  
In 1952, Halawani et al. reported Q fever seroprevalence data in ruminants (cattle 9.3% 
[16/172], buffalo 33.3% [6/18], goat 26.7% [4/15], sheep 6.5% [14/217]) and humans 
(cattle farm workers 14.3% [11/77]) in Egypt for the first time [140]. Since then, 
seroprevalence of the Egyptian population was reported from different geographical 
areas between 10-32% in human adults and 22% in children [138, 141, 142]. In 
Egyptian livestock, Cb-specific antibodies were detected in up to 13% of cattle, 4% of 
buffaloes, 33% of sheep, 23% of goats and 70% of camels (Tab. A1). Whereas 
seroprevalences in livestock of other African countries was found to be as high as 55% 
in cattle, 4% in buffaloes, 33% in sheep, 24% in goats and 80% in camels [133, 139, 
143, 144]. 
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For epidemiological purposes, the use of genomic analyses of Cb isolates allowing 
regional distribution of genotypes is very helpful [40, 48, 51, 54, 118, 145, 146]. 
Nevertheless, the risk of infection depends on various parameters such as environmental 
factors or animal and human population density. Although Q fever seems to be present 
nearly worldwide it should be stressed that generalization of data is problematic. It has 
also been shown that the prevalence measured at herd/flock level in a country is often 
higher than the seroprevalence within a single herd/flock. This in turn means, that only 
few infected animals seroconvert in each herd, though a herd is considered positive 
when at least one animal was tested positive [103]. Findings using convenience 
sampling make comparison often difficult. Table A1 gives a summary of different 
seroprevalence studies in Egypt and bordering countries highlighting the results and the 
diagnostic method and study design used. 
 
 
3.3 Coxiella burnetii 
3.3.1 Role as Biological Agent 
The U.S. Centers for Disease Control and Prevention (CDC) classified Cb as 
Category B biological agent [147]. These agents are characterized by a moderately easy 
dissemination, low mortality and a modest morbidity. Additionally, a specific enhanced 
diagnostic capacity and disease surveillance is needed. 
Dissemination of Cb is facilitated by different factors. First, a lot of easily accessible 
and susceptible hosts are available for Cb although the role of most hosts regarding 
dissemination is not clear. Excretion of the pathogen leads to environmental 
contamination. The special morphological characteristics of Cb mentioned allow 
surveillance in the environment for a long period of time. Consequently, Cb may be 
disseminated over a long period and thus increasing infection risk for humans and 
animals. The infection dose of 50% (ID50) is one to ten bacteria [113]. A “single 
organism theory” was created due to the low infection dose of less than 10 organisms in 
humans [1]. Cb has the ability to cause Q fever in large numbers of humans and animals 
[113]. Hence, Q fever has a high socioeconomic impact and is a serious threat for 
animals and civilians as well as for military personnel. This was shown during the last 
big Q fever outbreak in the Netherlands and in the military history of Q fever [64]. 
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Consequently, Cb was produced and weaponized in high numbers during several 
programs of biological warfare [113]. 
Because of the rising number of Q fever outbreaks, the disease is considered as re-
emerging infectious disease in humans as well as in animals. Nowadays, Q fever in 
humans is a notifiable disease in 17 and in animals in 14 EU member states including 
Germany [148]. Only specialized laboratories like reference laboratories are allowed to 
handle and further process Cb under biosafety level 3 conditions. 
 
3.3.2 Excretion Routes 
Domestic ruminants like cattle, sheep and goats are considered as primary animal 
reservoirs and the main source for Q fever outbreaks in humans [12, 101-103]. 
Cb-specific antibodies, however, can also be detected in many other hosts like horses, 
dogs, cats or pigs although their potential in bacterial shedding as well as their role in 
transmission is not clear yet [105-110]. For example, pigs can be infected with Cb but 
the assumption is that they pose a low infection risk for humans due to low prevalence 
(antibodies and DNA detection) and specific keeping system, although transmission 
could not be excluded [109]. Free roaming dogs from aboriginal communities had a 2.8 
times higher risk of being seropositive than others (e.g. household dogs) in Australia but 
evidence regarding bacterial shedding is lacking [149]. In Egypt, 23% of dogs were 
seropositive [150]. Cats may play an important role in human infection, although their 
role is still not fully investigated [110, 151, 152]. DNA could be detected in infected 
(parturient) as well as in healthy cats [153, 154]. 
Various bacterial excretion routes were described for Cb. It has been shown that they 
are host dependent in particular in ruminants. Furthermore, it is suggested that shedding 
differs among herds and flocks of the same species [155]. 
It has been demonstrated that the Q fever pathogen shows organ tropism towards the 
placenta [11]. In intranasal infected pregnant goats, DNA of Cb could be detected first 
in the upper respiratory tract followed by the uterus and placenta. Afterwards DNA was 
detected in rising numbers in organs of the dams and the kids until parturition, but the 
amount of DNA decreased afterwards [11]. Roest et al. assumed that Cb mainly 
replicates in the placenta organ [11]. Up to 109 bacteria are excreted per one-gram 
placenta tissue [8]. Consequently, the most important shedding route in small ruminants 
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is via birth products such as placental membranes and birth fluids during parturition or 
abortion [3, 8, 11, 156, 157]. It should be emphasized that excretion of Cb is 
independent of the delivery of dead or living offspring. Hence, parturition of offspring 
born alive should be considered as further source of infection for humans as well as 
herds or flocks [11, 158]. Cb has also been detected in milk, feces and vaginal mucus of 
small ruminants [11, 155, 157, 159, 160]. Rodolakis et al., however, found that the main 
excretion route in caprine herds was via milk whereas in ewes with an abortion 
background, DNA of Cb was mainly detected in feces and vaginal mucus and only to a 
lesser extent in milk [155, 159]. Joulié et al. demonstrated that bacterial burden was 
higher and shedding was longer in ewes with abortion or normal primiparous delivery 
than in non-aborting or multiparous females [159]. Hence, possible environmental 
contamination should be considered regarding results of feces and vaginal mucus 
samples to avoid misidentification of Cb shedders [11]. Experimental infected goats 
excreted Cb in milk until 38-52 days post inoculation depending on the milking pattern 
[8, 11]. It has been shown that Cb shedding in milk could be intermittent as well as 
continuously [155]. In naturally infected dairy sheep flocks Cb was shed at least two 
months in feces and three months in vaginal mucus [159]. 
In cattle the preferred shedding route of Cb is via milk although excretion routes via 
feces and vaginal mucus have been reported [13, 155]. Shedding could be independent 
of an abortion background and abortions are less prominent than in small ruminants 
[13]. Excretion might be irregular and may last for more than one year [155]. Little is 
known about excretion routes in buffaloes. One study showed that DNA could be 
detected in samples in all described routes in nearly the same numbers. In that study, 
milk was not the preferred route in buffaloes as seen for cattle [161]. 
In camels, little is known about the pathogenesis and excretion pathways of Cb despite 
the rising number of camel farms in many countries. Cb was detected in urine, blood, 
feces and in milk but no preferred excretion route was mentioned [104]. 
In summary, it can be said that despite all efforts dealing with pathogenesis of Cb and 
excretion routes in recent years both have not been discovered completely yet. 
Excretion routes are “used” to a variable extent and very often not simultaneously. 
Additionally, shedding is often discontinuously for all ruminant species in all described 
routes [13, 158, 159]. 
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Comparison of the excretion routes in domestic ruminants shows that ewes shed Cb to a 
higher extent and over a longer period of time in vaginal mucus than goats. Both animal 
species can shed Cb during successive pregnancies [162, 163]. Milk shedding, however, 
is more frequent in goats and cattle [164]. The most important excretion route affecting 
the transmission of Q fever and the risk of infection for humans and animals is via birth 
products during abortion and parturition. High environmental contamination is a result 
of this massive bacterial excretion. After drying, Cb may become aerosolized and 
disseminated by the wind very effectively [3, 165]. It has been proven that small 
ruminants were more often related to human Q fever outbreaks than herds of cattle [10, 
12, 101, 155]. These findings might also be explained by the different animal keeping 
systems e.g. ovine flocks are free ranged whereas dairy cows are kept and calve very 
often in stables. Therefore, the evaluation of infection risks is indispensable. 
 
3.3.3 Ways of Transmission 
As a zoonotic disease, Q fever can spill over to humans from infected animals or be 
transmitted from animals to animals. Certain characteristics of Cb allow survival for a 
long time outside the host e.g. in animal feces for two years or in dried blood for six 
month, respectively [166]. Hence, environmental contamination may last for years. 
Pathogen containing aerosols may be spread via the wind for probably several 
kilometers and may be inhaled [18]. Inhalation of contaminated aerosols such as water 
or dust is the main transmission route in humans as well as in animals [3, 11, 64, 167]. 
It has been shown that animals could also be infected through oral uptake or 
experimentally by subcutaneous inoculation [8]. In humans, transmission through oral 
uptake of unpasteurized milk and percutaneous or vertical infection has been 
documented [168]. Infection via tick bites has not been proven yet and the role of ticks 
in Q fever transmission is under discussion [120]. Recent studies focusing on Cb 
transmission via tick bite should be reflected critically, respectively. Infection risk for 
humans through drinking blood of infected animals and consumption of pathogen 
containing raw milk or unpasteurized dairy products is also still unclear [15]. 
Investigations of unpasteurized cheeses of small ruminants showed that 27/84 (32%) of 
cheeses were PCR positive and nearly two-thirds were non-handicraft (industrial) 
cheeses [16]. Whether the organisms in these products were infectious or not was not 
researched. Nevertheless, the result for industrial dairy products (cheeses, yogurts, 
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creams, butters) was also confirmed by Eldin et al. [169]. He detected Cb-specific DNA 
in 64% of examined dairy products (n = 201). Evidence of viable Cb was negative and 
dairy products made of unpasteurized milk contained more DNA than food made of 
pasteurized milk. Products made of small ruminant milk were not as frequently PCR 
positive than those made of cow milk [169]. 
Q fever transmission from “person to person” is seldom and only few cases were 
reported. Nevertheless, sources of infection varied including respiratory transmission 
after autopsy and infection after receipt of blood transfusion or a bone marrow 
transplant [170-172]. There was one report found of an obstetrician’s infection and 
vertical transmission from a pregnant woman to her fetus [173]. 
 
3.3.4 Potential Risk Factors 
In general, infection of humans and animals occurs through direct or indirect exposure. 
Factors like animal species, number of animals kept in an area or country and type of 
animal keeping system are closely connected to the risk of infection [12, 131, 156, 174, 
175]. 
Q fever outbreaks in humans in the Netherlands (2007-2011) were mainly associated 
with goats due to the high number of goat farms [12]. In Germany, in contrast, more 
sheep than goats are kept. While sheep often range free through the landscape and graze 
in rural areas, goats and cattle are kept in dairy farms in villages or even small cities 
[12, 131, 175]. Since environmental contamination happens mainly through extensive 
animal keeping, farms in close proximity to urban areas increase the risk of infection for 
other animals as well as for humans. The inner-herd prevalence might be also affected 
by intensive keeping systems [175]. Therefore, it is likely that merging of herds or 
flocks from different animal keepers, as it can be seen in many African countries, 
facilitates spread of Cb within herds and in an area as well. Cb circulates in herds and 
flocks and it is assumed that synchronized production systems (with one main lambing 
season) in small ruminants result in seasonal peaks of human and animal infections [6, 
18, 102, 165, 176]. Hence, the immune status of the whole flock or herd and of the 
individual animal itself plays an important role in Cb spreading [12, 156, 174]. Poor 
farm and hygiene management such as missing quarantine including health check-up of 
new animals brought to the farm and removal of afterbirths should be considered as 
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spreading factors. It has been shown that Cb DNA can be detected in dust and air 
samples from the animal houses for several months although individual shedding 
stopped before [159, 177]. 
Spillover to humans and other animals is also associated with risk factors such as 
specific environmental conditions or proximity to infected animals (especially small 
ruminants) as well as their production and processing sites. Environmental conditions 
include geography, landscape and climate conditions. Several Q fever outbreaks in 
humans were associated with close contact to goat farms or sheep flocks ranging and 
grazing near villages and contaminating the surrounding environment as mentioned 
above [12, 131, 165]. Investigations of Swedish dairy cattle herds revealed that herds in 
open landscapes with high temperature, low precipitation (high precipitation decrease 
aerosol formation) and high wind speeds have an increased risk of being seropositive 
[17]. However, a naïve cattle herd could only be infected when contaminated aerosols 
contain enough bacterial load and are transported from infected sources with high wind 
speed (>5.5 m/s) [178]. In Tanzania, onset of illness in humans was recognized during 
the dry season [179]. 
It seems that the risk of infection with Cb is often limited to rural areas. Transport or 
loss of contaminated animal bedding or manure during transport and animal movement, 
however, bear a high risk for further dissemination of Cb besides wind spreading [64, 
113, 131]. Therefore, people in urban areas may become affected. Q fever bears a 
substantial risk for specific occupational groups with close contact to infected animals 
or their products such as veterinarians, abattoir workers and farmers [146, 180]. Sheep 
shearing and working in the wool industry is also correlated to a high risk of infection 
as pathogen containing tick feces is present regularly in the wool [181]. Consumption of 
raw milk and unpasteurized dairy products is considered as a risk factor, although 
evidence is missing [169]. Different African traditions such as consumption of raw milk 
or even blood of animals have been identified as further risk factors in Kenya [182]. 
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4 Laboratory Diagnosis 
Q fever diagnosis is a challenge in animals as well as in humans. Especially in 
ruminants, the appearance of clinical signs i.e. abortions initiate Q fever diagnostics 
usually. Diagnostic techniques for Cb infections are based on isolation and cultivation 
of the pathogen, detection of its DNA (direct diagnostic methods) and detection of 
Cb-specific antibodies using serological methods (indirect diagnostic methods) [11, 
183]. Routine diagnostics usually involve serological methods and PCR only. 
In humans the disease is often misdiagnosed due to various clinical presentations and 
confusion with influenza or malaria [179, 184]. Therefore, history of exposure and 
medical history should be investigated in detail. Serological methods are standard in 
human diagnostics and phase specific diagnostic techniques are available. 
 
 
4.1 Q fever – Clinical Symptoms and Signs 
Cb is the etiological agent of Q fever. Nowadays the term “Q fever” is accepted for the 
disease in humans and animals. In animals, Q fever was called coxiellosis before. Only 
one to ten bacteria are necessary to infect humans as well as animals. Incubation time is 
considered to be 2-3 weeks until the first symptoms in humans and clinical signs in 
animals become obvious. Usually the infection remains asymptomatic. 
 
4.1.1 Human Disease 
Humans at any age and gender may become infected with Cb and may develop Q fever. 
The infection can be asymptomatic or manifests with unspecific symptoms. Nearly 
every organ system may be affected [64]. Asymptomatic Q fever infections are 
common. Acute as well as chronic disease courses are known and may be differentiated 
through their serological profile [7]. 
Most (50.0-90.0%) of seroconverted people are asymptomatic [3, 131, 185]. Those 
asymptomatic patients may develop chronic disease. The risk to develop chronic 
Q fever increases, if treatment is not administered timely and is regularly seen in high 
risk groups such as patients with an (un)known pre-existing heart valve diseases. 
Additionally, Q fever is often misdiagnosed due to unawareness of physicians, the 
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nonspecific and various clinical manifestations and the lack of efficient rapid diagnostic 
methods resulting in delayed diagnosis several months after onset of illness [186, 187]. 
The acute stage is characterized by mild clinical symptoms (38%) and hospitalization is 
required in approximately 2% of infected patients [3]. The mortality rate for acute 
Q fever is approximately 2% [188, 189]. Clinical manifestations similar to influenza, 
pneumonia and hepatitis are seen [190]. It is assumed that manifestation of acute 
Q fever depends on the infection route [191]. Q fever is often described as a self-
limiting flu-like disease with symptoms like cold, fatigue, malaise, myalgia, headache, 
shivers and sweats [19, 37]. Interestingly, fever is not always present but prolonged 
fever is often seen [23, 192]. Derrick et al. described a reappearing biphasic fever curve 
in one quarter of acute Q fever cases [192]. Additionally, it has been shown that Q fever 
is also a cause of fever of unknown origin (FUO) and thus a diagnostic challenge. In 
Africa, Q fever was the reason for hospitalization of 2-9% of all patients hospitalized 
with febrile illness [136]. In northern Tanzania Q fever is also one of the most common 
causes in febrile patients [179, 184]. Twenty-eight percent (n = 50) of Egyptian patients 
with FUO had Cb-specific antibodies in their first serum sample and further patients 
with FUO (12%) showed a seroconversion in their convalescence sera [138]. Atypical 
pneumonia is the most common manifestation, but clinically asymptomatic and rarely 
respiratory distress may be seen [3, 193]. Minimally auscultatory anomalies, 
nonproductive cough and fever are the main symptoms [193]. Hence, new diagnostic 
strategies focus on X-Ray [194]. Pneumonia is often noticed together with other 
symptoms. Hepatitis, i.e. hepatomegaly with rare jaundice, clinically asymptomatic or 
granulomatous hepatitis are noticed [195, 196]. Increased liver enzyme levels are the 
consequence. Many other manifestations of acute Q fever infection have been 
recognized in nearly every organ system but are less common. For instance, 
neurological (e.g. encephalitis, meningoencephalitis), cutaneous (e.g. rash, erythema 
nodosum) or cardiac (e.g. myocarditis, pericarditis) symptoms may be seen [3, 6, 189, 
197]. Myocarditis (<1%) is a lifelong sequela and is described as the main cause for 
fatal outcome of Q fever [3, 6, 198, 199]. 
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In chronic Q fever the disease is present longer than six months [200]. This chronic 
stage may be seen months and even years after an unrecognized or acute Q fever. 
Between 0.2% and 5% of infected patients develop chronic Q fever involving the 
cardiovascular system, the skeleton (osteoarticular) and the liver [5, 201-204]. 
Especially pregnant women and patients with predisposing factors as cardiovascular 
lesions, cirrhosis, immunosuppression or cancer are risk groups for developing chronic 
Q fever [6]. Several strategies have been discussed for early chronic Q fever detection 
but no standardized criteria could be identified for screening. Till today, there is no 
uniform case definition for chronic Q fever [205-207]. Assessment of possible 
pre-exposure of asymptomatic or unknown chronic infected humans and follow-up of 
acute Q fever cases could support diagnostics of chronic Q fever. For instance, at least 
one follow-up (six or nine months post infection) is recommended in acute Q fever 
patients with unknown risk [201, 208]. Patients with high risk of developing chronic 
Q fever such as patients with clinical cardiac abnormalities should be routinely 
examined using echocardiography to avoid fatality due to delayed diagnosis [208-210]. 
Nevertheless, it is recommended to examine patients with an indication only to avoid 
overestimation of cardiac disorders due to Q fever. 
Endocarditis is the most common chronic manifestation (60-73%, 0.6-7% of acute 
Q fever cases), especially in people with unknown Q fever infection and/or predisposed 
(un)known cardiac valve or vascular defect or in immunocompromised patients [3, 6, 
201-203, 211-213]. Several studies identified Cb as cause of endocarditis (3-5%) [214, 
215]. In Africa, Q fever was responsible for 1-3% of all infective endocarditis cases 
[136]. Mortality rate for endocarditis cases decreased due to better diagnosis and 
treatment but is still approximately 5% [6]. Additionally, high relapse rates are 
described after withdrawal of antibiotics [187]. Further cardiovascular consequences 
e.g. arterial embolism, infection of aneurysms or vascular grafts are described [202, 
216-218]. Chronic hepatitis or in its worst case cirrhosis, has been diagnosed in chronic 
liver manifestation [3, 202]. If the skeleton is affected, osteomyelitis, osteoarthritis and 
contiguous vertebral osteomyelitis (as consequence of aortic graft infection) are likely 
[219, 220]. Chronic fatigue syndrome is also discussed as a long term sequela [209, 
221-224]. Cases of various rare manifestations e.g. chronic pulmonary infections were 
described [3]. 
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Q fever in children manifests with nearly the same symptoms as described for adults. 
Acute cases are often self-limiting with fever or asymptomatic. Whereas chronic 
infections are characterized by osteomyelitis, endocarditis and fever relapse [225-227]. 
Pregnant women have a particular risk of contracting Q fever as it is known to cause 
reproductive disorders especially abortions. Most reported Q fever infections in 
pregnant women were asymptomatic with healthy infants [228, 229]. This might be one 
reason for the limited available case reports on reproductive disorders in women and 
thereof most described abortions [173, 199, 228-230]. In southern France, pregnant 
women (n = 23) suffered from premature birth (35%), abortion or neonatal death (43%), 
and intrauterine fetal death was also described [199, 229, 230]. Further complications 
such as placentitis, fever and thrombocytopenia are described and should be examined 
carefully in pregnant women for detection of Cb as possible cause [151, 173, 230-232]. 
Asymptomatic infection during pregnancy bears the risk of developing chronic Q fever 
and the risk of resurgence during further pregnancy [199]. 
More men than women are infected e.g. in France (2.5:1) and Australia (5.3:1) [6, 132]. 
These findings may be explained by occupational exposure as demonstrated for 
Egyptian cattle workers [138]. Nevertheless, it has also been demonstrated that causes 
for Q fever infection are not always linked to occupation or rural lifestyle.  
Hospitalized younger patients developed hepatitis more often whereas pulmonary 
involvement was more frequent in older patients. Both manifestations were more 
frequently diagnosed in men [6]. 
Some clinical findings are predominant in different countries and within certain areas. It 
was suggested that these findings depend on the variable virulence of local Cb strains 
and the infection route. Pneumonia, for instance, is a major clinical manifestation in 
Nova Scotia, in the Basque region of Spain and in Switzerland, whereas hepatitis was 
prominent in France and southern Spain [189, 233-235]. In Australia, however, febrile 
manifestation was predominant [190, 192]. 
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4.1.2 Disease in Animals 
Cb infections in animals are often subclinical and asymptomatic although Cb-specific 
antibodies can be detected in various animal species. Interestingly, some specific Cb 
strains are correlated with different ruminant species [54, 236, 237]. Ruminants show 
clinical signs involving abortion as well as premature delivery, stillbirth and weak 
offspring. Agerholm designated these manifestations as APSW (abortion, premature 
delivery, stillbirth, weak offspring) complex [238]. In contrast, delivery of healthy 
offspring is also described and correlated with shedding of bacteria in high numbers 
[11, 13, 158]. These clinical signs are outcomes of the intrauterine infection due to the 
specific organ tropism of Cb (Fig. 5). Factors like gestation age, virulence of Cb strains, 
immune response (maternal and fetal), spreading (haematogenic or amniotic oral) and 
dissemination in the fetus may influence the disease outcomes [238]. 
The phenomenon of seropositivity but asymptomatic course of infection can be 
regularly seen in small ruminants (sheep and goats). If clinical signs are seen in 
pregnant small ruminants, the most conspicuous characteristics are stillbirth and 
abortion. This is especially evident during late pregnancy, whereas no clinical signs are 
observed in non-pregnant goats [3, 8, 9, 156]. Roest et al. assumed that premature death 
of fetuses is missing, because the trophoblast cells of the allantochorion (primary target 
cells of Cb) of pregnant goats covering the cotyledonary villi are not affected by Cb. 
This allows the maintenance of gas and nutrition exchange between maternal and fetal 
tissues. These findings are divergent to brucellosis or chlamydial infections [11]. 
Although placentitis, characterized by a purulent exudate on areas between cotyledons, 
may be seen (microscopically), the aborted fetuses look fresh and are rarely autolyzed 
[9, 239]. No clinical signs were recognized in most pregnant goats before abortion at 
late pregnancy [240]. Experimentally infected pregnant goats and ewes, however, 
showed fever and Cb could be detected in different organs (blood, lung, spleen, liver) 
during the acute phase [8, 9, 11, 241, 242]. It is still unclear whether Cb affects these 
organs because only mild lesions have been recognized [3, 9]. Further clinical signs 
such as metritis are observed in goats with abortion background. Additionally, the living 
offspring was born weak with reduced body weight or with e.g. respiratory disorders 
[156]. Reproductive problems during the season following an abortion storm are not 
striking in sheep and goats [156, 162, 174]. 
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Cattle are frequently asymptomatic. Experimental infections in cows (n = 6) and heifers 
(n = 12) demonstrated that they may develop acute Q fever with e.g. fever and self-
limiting pneumonia [243, 244]. Two abortions in this group of infected animals only 
support the present idea, that the abortifacient potential of Cb in cows is still low and an 
infrequent cause (also on herd level) in field situations [243, 245-247]. Compared to the 
epidemic (herd level) occurrence in sheep and goats, reproductive disorders are sporadic 
in cattle. Abortions are more often correlated with other infections such as Chlamydia 
spp. or Neosporum canis [248-250]. Cb, however, can be detected in the placenta of 
asymptomatic and symptomatic cows as well as in birth products or aborted fetuses. 
Mild lesions as well as placentitis may be found in the placenta as well [13, 155, 245-
247, 251]. Nevertheless, mastitis, especially subclinical, is the most common obvious 
Q fever manifestation in cows [252]. Clinical signs like metritis or infertility are 
discussed as consequence of placental infection of Cb, but evidence is often lacking due 
to missing case definitions and specific examinations [238]. Knowledge about Cb 
infections and their effects on bulls are lacking. Although, Cb can be detected in semen 
[253]. 
Antibodies of Cb were detected in other animal species like horses, pigs, dogs and cats. 
But the role of Cb regarding reproductive disorders, especially as cause of abortion, in 
those species is unclear [105-109, 151, 152]. One Q fever outbreak in humans was 
described and associated with a parturient dog losing all puppies within one day after 
birth [254]. Parturient cats with clinical signs like stillborn or unhealthy kittens, 
however, are correlated to several human Q fever outbreaks [110, 152, 255, 256]. 
However, DNA was isolated from healthy cats as well [154]. 
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Figure 5. Estimated consequences of a Coxiella burnetii infection in the uterus of 
pregnant animals. 
Cited from Agerholm, 2013. 
This schematic figure is based on the present knowledge indicating that an intrauterine 
infection with Cb may have different outcomes in pregnant animals. The green arrows 
indicate the route of a latent infection of which the outcome is very common, at least in 
cattle. Whereas an active infection, marked by red arrows, most likely affects the fetus 
after hematogenous or amniotic-oral spreading. 
APSW = abortion, premature delivery, stillbirth, weak offspring complex 
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4.2 Diagnostic Methods for Q fever Detection 
4.2.1 Cultivation of Coxiella burnetii 
Cb may be isolated and propagated in different cell lines or under axenic conditions. 
Nowadays, the use of laboratory animals in Germany is subject to strict legal 
regulations according to the animal protection law considering animal welfare. Thus, 
laboratory animals are not used for cultivation any longer despite their very successful 
use in the past [19-21]. The use of laboratory animals e.g. mice or guinea pigs had 
specific benefits: guinea pigs are very susceptible to Cb infections, the influence of 
microbial contamination of a sample is restricted and the pathogen can be isolated from 
spleen tissue for further processing [20, 257, 258]. 
Cb may also be propagated in high numbers in the yolk sac endoderm of embryonated 
hen eggs [24, 259]. A drawback herein is the shift of the bacterium to Phase II 
associated with loss of virulence. Additionally, purification of the Q fever pathogen is a 
long and difficult process [260]. 
In vitro the Q fever agent replicates in different cell lines such as epithelial, fibroblast 
and macrophage like cell cultures. Such cultures were used since the first Cb cultivation 
experiments in 1937. Cell lines like Vero cells (African green monkey kidney cells) or 
L929 mouse fibroblast cells are used often [6, 20, 33, 62, 261]. The sensitivity of Cb 
against some antimicrobial substances should be taken into account to ensure success of 
cultivation [262].  
A milestone in Cb cultivation was the development of an axenic growth medium, the 
acidified citrate cysteine media (ACCM), in 2008 [257, 263]. Cb can be cultured over 
14 days and undergoes developmental differentiation in this medium. ACCM 
cultivation allows direct cultivation and phenotypic and genotypic characterization of 
Cb isolates [264]. It is still unclear whether the virulence of Cb isolates is affected by 
repeated axenic propagation. ACCM is a useful tool for isolation from clinical samples 
[257, 265-267]. Nevertheless, success will always depend on bacterial load of the 
sample, virulence of Cb isolates and microbial contamination [257, 267]. 
It should be emphasized that cultivation method can only be performed under biosafety 
level 3 laboratories by specialized staff. It is time consuming and not useful for quick 
routine diagnosis. 
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4.2.2 Polymerase Chain Reaction 
Cb may be detected using polymerase chain reaction (PCR) technique. Especially 
quantitative real-time PCR (qPCR) assays are used [268]. In general, PCR is based on 
the detection of specific DNA sequences and proven to be a sensitive and rapid 
detection method. Specific single copy genes like com1 and icd or the multi copy 
IS1111 element of the pathogen can be targeted [43, 268]. The copy number of the 
IS1111 element varies in different Cb isolates and it can also be found in 
Coxiella-like bacteria. These findings hamper the use of the IS1111 assays for 
quantification and identification of Cb in environmental samples although it is known as 
the most sensitive assay [43, 128, 269]. For PCR analysis samples such as milk, feces 
and vaginal mucus or birth products of animals can be used. It has to be kept in mind 
that environmental contamination of samples such as feces or vaginal mucus, might 
give false results and serological diagnostic methods are used frequently instead or both 
in combination [11, 183]. Blood samples will only test positive in the initial bacteremic 
stage of infection before antibodies are detectable. In humans, it has also been shown 
that PCR is not useful for early Q fever diagnosis whereas a high sensitivity was noted 
for pathogen containing tissues like heart valves [270, 271]. 
 
4.2.3 Antigen Detection 
The use of specific antibodies reflects a wide field of diagnostic techniques including 
immunohistochemistry (IHC) or immunofluorescence (IF). IHC is applied in Q fever 
diagnostics for examination of tissues and detects specific cell structures or antigens 
(epitopes) of Cb with specific antibodies conjugated to dyes. In the IF technique 
fluorescent dyes are applied. Histological slides may be prepared from tissue samples of 
aborted fetus or placenta [9, 11]. Gram or Gimenez staining of smears and other sample 
preparations are unspecific and variable. Other staining techniques like the modified 
Ziehl-Neelsen stain are also unspecific and might result in misdiagnosis, e.g. 
Chlamydia abortus or Brucella abortus also appear as red colored coccobacilli after 
staining and are indistinguishable from Cb [32, 64]. Histological sections and smears 
can also be analyzed by indirect IF. IF or IHC methods are helpful tools in research to 
reveal etiology and pathogenesis of Cb, but not in the veterinarian routine diagnostic 
laboratory. 
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4.2.4 Antibody Detection 
For Q fever diagnosis complement fixation tests (CFT) and enzyme linked 
immunosorbent assays (ELISA) are routinely used [64]. Indirect immunofluorescence 
assays (IFA) are used less frequently and are not commercially available for veterinary 
medicine. In general, ELISAs have certain advantages over methods mentioned above. 
They are easy to handle, time- and cost-efficient. Milk and blood samples can be 
analyzed in a high throughput format. Especially, examination of bulk tank milk (BTM) 
by ELISA allows easy herd screening and monitoring of dairy cattle, goat and sheep 
farms with a fast turnaround [155, 239, 272]. Drawbacks of Q fever ELISAs are the use 
of mixed whole cell antigens from Cb (PhI and PhII) and the detection of only IgG 
isotypes instead of IgG and IgM [273]. CFTs are based on PhI, PhII or PhI and PhII 
mixed antigens and can detect IgG as well as IgM antibodies. Several studies comparing 
CFT and ELISA revealed that some animals may be seronegative in the ELISA 
technique whereas low positive CFT titers are found [273-276]. This finding was 
explained by the reactivity of the CFT to IgM and the lack of the PhII response 
(associated to IgM because of early production of PhII antigens in infection) [274, 275]. 
Based on these observations the sensitivity of current commercial available ELISAs is 
intensely debated although ELISAs are considered to have a better sensitivity and 
specificity than CFT in general [272, 275, 277, 278]. Furthermore, EFSA recommended 
ELISAs in combination with PCR for Q fever diagnosis in animals [164]. 
Anti-complementary activity is a known problem in CFTs leading to untestable results 
[148]. 
 
4.2.5 Human Medicine 
All the above-mentioned diagnostic techniques are also applied in human medicine. In 
contrary to veterinary medicine, phase specific ELISAs are available and supported by 
various diagnostic cutoffs and case definitions [7, 164]. During an acute Q fever 
infection, PhII specific IgM antibodies and IgG are detected within the second week 
post infection. Whereas PhII titers steadily increase, low titers of PhI-specific IgM and 
IgG are detected during convalescence (successful treatment or spontaneously self-
limiting) [7, 279]. Anderson et al. (CDC and Q fever working group) recommended for 
the diagnosis of acute Q fever besides clinically symptoms: a fourfold rise of PhII IgG 
(IFA) in a paired acute and convalescent blood sample (3-6 weeks), illness longer than 
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one week and a single positive convalescent serum sample with PhII specific IgG titers 
≥1:128. For definitive diagnosis of acute Q fever, however, a combination of PCR and 
serological testing is necessary [7]. PCR testing is only useful in the first two weeks 
after infection and at least 24-48h after onset of antibiotic treatment. Chronic Q fever is 
mostly characterized and diagnosed by a constantly increasing PhI-specific IgG titer 
(titers ≥1:1024) and a comparable low PhII-specific IgG titer [7]. It has been shown that 
IgG titers ≤1:400 have a negative predictive value (100%) whereas IgG titers ≥1:1,600 
(or IgG titers >1:800 and IgA titers >1:50) indicate a positive predictive value of 97% 
(or 94% for IgG and IgA titers) for chronic Q fever [6, 280]. PhI IgG titers ≥1:800 are a 
specific criterion for endocarditis [7, 279]. 
In human medicine, a skin test, an intradermal hypersensitivity test, is used besides 
serum antibody estimations before vaccination. This pre-vaccinating testing detects 
hypersensitivity reactions to the vaccine that may result from unrecognized exposure to 
Cb. Blood sampling and skin test should be done the same day. The skin test is read and 
the result is interpreted after seven days. Vaccination is indicated if both results are 
negative and the person has a negative history of previous infection with Cb [180, 281, 
282]. 
 
 
4.3 Correlation of Diagnostic Results with Shedder Status in Animals 
Correlation of diagnostic results with shedder status is a challenge in Q fever diagnosis. 
Rodolakis et al. observed bacterial shedding in ewes of which 80% were seronegative 
[155]. It has been shown that goats may also be seronegative and excrete Cb in e.g. milk 
or vaginal mucus during parturition [8, 11, 155, 158]. It was observed that antibody 
titers against PhII increased in infected goats at least ten days before delivery [283]. In 
dairy cattle a similar phenomenon was described and the pathogen was excreted 
intermittently or frequently in all possible routes [252, 272]. Approximately 35% of Cb 
shedders had a positive result in the ELISA only, but frequent shedding in milk was 
correlated to persistent high seropositive results [155]. In dairy cattle rising PhI-specific 
antibody titers were correlated to frequent shedding of Cb via milk [13, 274, 284]. 
Böttcher et al. found that chronic milk shedders may be correlated to a PhI titer ≥1:500, 
whereas puerperal shedding was indicated by a PhI antibody negative and PhII antibody 
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positive pattern in primiparous cows [284]. Muskens et al. mentioned that young cattle 
had negative fecal PCR results and only 1% was seropositive whereas higher 
prevalences were detected in the adult group. This finding was explained by the 
suggestion that young cattle become infected after re-grouping into the adult herd [272]. 
Re-grouping may be stressful for these young cattle and may cause immunosuppression. 
Lack of commercially available and verified phase-specific diagnostic methods in 
veterinary medicine hampers differentiation between a previous and a present infection. 
Current serodiagnostic methods are unable to differentiate between Q fever infected and 
vaccinated animals [277]. Therefore, the development of DIVA vaccines is essential, 
since Cb-specific DNA from the current vaccine composed of the inactivated PhI Cb 
was detected in goat milk shortly after vaccination [285]. To solve this problem and to 
improve sensitivity and specificity, new development strategies in Q fever diagnostics 
concentrate on the identification of immunogenic proteins and peptides that will replace 
whole cell antigens [286, 287]. 
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5 Therapy and Prevention 
5.1 Therapy and Management of Q fever in Humans 
Besides the fact that acute Q fever is often self-limiting within 2-3 weeks even without 
therapy, antibiotic treatment is recommended. The most effective antibiotic and first 
choice of treatment of adult acute Q fever patients and children ≥8 years is doxycycline 
administered for two weeks. If doxycycline is contraindicated, other antimicrobial 
chemotherapeutic regimes can be chosen (e.g. trimethoprim/sulfamethoxazole, 
clarithromycin, rifampin) [288-290]. To reduce the risk of further complications and to 
shorten the time of illness and accelerate recovery, treatment should be started at least 
on the third day after onset of symptoms [193, 289, 291, 292]. Consequently, treatment 
of suspected Q fever cases should start after clinical diagnosis without laboratory 
confirmation. It is not routinely recommended in asymptomatic cases or patients with 
mild symptoms [291, 292]. Additionally, patients with acute Q fever should be carefully 
examined by practitioners whether they belong to one of the groups having a higher risk 
to develop chronic Q fever e.g. patients with pre-existing (un)known cardiovascular 
diseases, immunosuppression or pregnant women. Those patients should carefully be 
monitored clinically and serologically in subsequent regular intervals to avoid non-
recognition of chronic Q fever progression and early start of treatment. Especially 
untreated endocarditis is often fatal. Fenollar et al. recommend a doxycycline therapy 
for one year for acute Q fever patients with valvopathies [213]. Trimethoprim/ 
sulfamethoxazole should be considered for acute Q fever treatment in pregnant women 
as this antibiotic may have less negative effects on the developing fetus than 
doxycycline [7]. They should be monitored after delivery to detect postpartum 
progression to the chronic stage as well as during the next pregnancies to notice Cb 
recrudescent timely. In children aged <8 years with mild symptoms, doxycycline (5 
days) or trimethoprim/sulfamethoxazole may be applied [7]. 
Diagnosed adult chronic Q fever patients should receive a combined antibiotic regime 
with doxycycline and hydroxychloroquine [3, 7, 187]. This combination ensures the 
bactericidal effect in vivo against Cb as hydroxychloroquine also raises the pH in the 
CCV. Hydroxychloroquine, however, should be used with caution and with additional 
ocular examination as it is known for its retinal toxicity (photosensitivity) during 
long-term use [187]. In patients with cardiovascular infections, treatment may last up to 
two years and decrease in antibody titers should be verified [187, 218, 293]. Surgical 
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interventions such as replacement of defect heart valves or removal of an infected graft 
may be necessary and live-saving. 
 
 
5.2 Management of Q Fever in Animals 
Therapy of Q fever in animals, in particular in ruminant herds and flocks, shall be based 
on farm management strategies and prevention measures rather than on 
chemotherapeutical treatment. During the Dutch Q fever outbreak, more than 50,000 
pregnant goats and sheep were culled between December 2009 and June 2012 to inhibit 
further Cb spreading [12]. Additionally, goats were vaccinated with an inactivated PhI 
vaccine. Vaccination seems to be the most effective tool in Q fever control. 
Nevertheless, in Germany for instance, a licensed vaccine (Coxevac, inactivated Nine 
Mile Phase I) is only available for cattle and goats and its use in sheep requires specific 
authorization. Confirmation of a positive effect of a combined treatment (vaccination 
and antibiotic) of infected dairy cattle could not be demonstrated [294]. 
 
 
5.3 Prevention Measures 
Primary objective in Q fever control is the reduction of the infection risk for humans 
and animals and the resulting positive impact on the socioeconomic burden. Therefore, 
prevention measures focus mainly on decreasing Cb shedding and dissemination to 
reduce environmental contamination within a farm as well as in the field. To achieve 
this, the implementation of a network relying on the One Health approach of 
epidemiologists, veterinarians and physicians is indispensable. In African countries, 
disease control efforts are missing, respectively, and implementation of diagnostic 
capabilities is needed [136]. 
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5.3.1 Farm Management and Environmental Control Measures 
On farms, management strategies should focus on reduction of Cb shedding in 
individuals as well as on prevention of Cb dissemination within herds, flocks and into 
the environment. 
Epidemic control and hygiene measures should include the acquisition of new animals 
only from Q fever negative tested herds/flocks and should include quarantine of animals 
during serological testing. Within herds/flocks, separation of pregnant animals and 
those that aborted, is recommended [113, 159]. Joulié et al. also proposed to separate 
primiparous ewes from the flock [159]. During the Q fever outbreak in the Netherlands, 
many pregnant goats and sheep but also bucks were culled and a vaccination program 
was introduced [12]. Arricau-Bouvery et al. also recommend an animal disposal 
program involving vaccination and elimination of shedders [241]. It has been shown 
that the current vaccines reduce excretion (especially in vaginal mucus, feces and 
particularly in milk) and abortions in goats, whereas effects in sheep could not be 
confirmed [241, 295-299]. Several studies showed, that vaccination in pregnant animals 
(cattle, goats) or parous goats is largely ineffective. Newborn kids and naïve bovids 
cannot be protected from Q fever infection [295-298]. Ineffectiveness in pregnant 
animals was presumed, because of the induced immunomodulation during pregnancy 
[295]. Infections in previously infected animals (goats, cattle) were also not cleared by 
vaccination [241, 295-298]. Consequently, like for diagnostics, new approaches in 
vaccine development are needed to induce a comprehensive immune response. 
Nevertheless, in uninfected and young animals future bacterial shedding may be 
decreased and vaccination is recommended [164, 272, 296]. Vaccination of herds/flocks 
next to infected herds/flocks may be helpful as well. 
Manure management is also an important and effective in-farm measure and includes 
e.g. composting of contaminated litter and manure, which reduces viability of Cb [300]. 
Animal birth and abortion products should be removed and eliminated conscientiously 
to prevent further dissemination of Cb. Legal requirements may be imposed including 
ban of animal movement and transport of infected animals, or even farm animal 
breeding as seen in the Netherlands [12]. Notification of increased farm animal abortion 
was made obligatory in the Netherlands and France [12, 164]. Hygiene management e.g. 
of personnel, disinfection of transport vehicles, utensils or even paths and indoor 
housing need to be considered. 
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Control and observation strategies such as regular testing of BTM are helpful to identify 
Cb shedders, but are not yet compulsory [155, 239, 272]. Additionally, data about the 
circulation of Cb within herds and flocks are useful for implementation and assessment 
of optimal farm management strategies [159]. It has been shown that the analysis of 
cloth samples from the environment e.g. of a barn is effective. Areas along fences or 
window ledges were wiped up with small cloths moistened with distilled water to 
collect dust [159]. 
 
5.3.2 Decrease of Risk of Infection and Impact of Q fever in Human Beings 
The One Health approach is based on cross-sectional collaborations (epidemiologists, 
physicians and veterinarians) addressing risks originating from the relation between 
humans, animals and the ecosystem. To decrease risk of infection and further impact on 
human health, public information and awareness rising measures are indispensable and 
must be guaranteed. 
To avoid further dissemination of Cb and spill-over, several restrictions may be 
implemented in high risk areas. Those may affect visiting of affected farms, livestock 
markets, human assemblies or blood donation [164, 301]. In France, restrictions also 
focus on trade of raw milk: sale of milk is forbidden for one year after diagnosis of 
Q fever in an animal out of a raw milk producing farm. Additionally, the milk of an 
aborted animal in a cheese producing farm has to be eliminated and pasteurization of the 
milk harvested from the remaining flock is needed [302]. Thus, pasteurization or 
sterilization of raw milk and prevention of raw milk and raw dairy products 
consumption decreases the risk of infection. 
It is necessary to raise awareness in physicians regarding Q fever diagnosis and 
anamnesis. Q fever is often not considered as differential diagnosis in particular in 
febrile patients. Thus, diagnosis especially in late and chronic cases is often delayed 
because of unrecognized illness rather than of long incubation time. 
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Nowadays, the most used vaccine in humans is Q-Vax. It is only produced and licensed 
in Australia and is composed of whole-cell PhI bacteria (formalin-inactivated 
Henzerling strain) [180, 303]. In humans with previous exposure to Cb local and severe 
systemic reactions were noticed. Hence pre-examination is indicative using the 
cutaneous test [180, 281, 282]. Vaccination is normally not performed in Europe, but 
this vaccine was used during the Dutch Q fever outbreak in people at risk of chronic 
Q fever [103]. Persons with an occupational risk may receive vaccinations compulsorily 
as a protective effect was seen in slaughterhouse workers in Australia [180, 303]. 
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S1 Table. Prevalence of Coxiella burnetii specific antibodies positive tested animals 
in Egyptian governorates. p < 0.001, n = number, n. a. = not available. 
 
Animal 
species 
Domain 
Governorate 
(n total sites/ 
n total farms) 
Serum positive 
n/total [%] (95% CI) 
Cattle Western Desert New Valley (6/6) 26/170 [15.3] (10.66-21.47) 
Matrouh (4/4) 34/170 [20.0] (14.68-26.65) 
Nile Valley a. Delta Alexandria (3/3) 0/12 [0.0] (0.00-24.25) 
Beheira (2/4) 3/12 [25.0] (8.89-53.23) 
Cairo (2/2) 0/12 [0.0] (0.00-24.25) 
Damietta (2/2) 1/12 [8.3] (1.49-35.39) 
Dakahlia (2/2) 1/12 [8.3] (1.49-35.39) 
Kafr El Sheikh (3/3) 1/12 [8.3] (1.49-35.39) 
Gharbia (3/3) 3/12 [25.0] (8.89-53.23) 
Sohag (2/2) 8/24 [33.3] (17.97-53.29) 
Ismailia (4/4) 2/12 [16.7] (4.70-44.80) 
Qalyubia (2/2) 0/12 [0.0] (0.00-24.25) 
Menoufia (3/3) 2/12 [16.7] (4.70-44.80) 
Minya (2/2) 2/12 [16.7] (4.70-44.80) 
Suez (2/2) 4/12 [33.3] (13.81-60.94) 
Sharkia (3/3) 3/12 [25.0] (8.89-53.23) 
Qena (3/3) 0/24 [0.0] (0.00-13.80) 
Port Said (2/2) 2/12 [16.7] (4.70-44.80) 
Luxor (0/0) n. a. 
Giza (3/3) 1/12 [8.3] (1.49-35.39) 
Fayoum (3/3) 1/12 [8.3] (1.49-35.39) 
Beni Suef (2/2) 1/24 [4.2] (0.74-20.24) 
Aswan (3/3) 10/60 [16.7] (9.31-28.03) 
Assuit (3/3) 6/36 [16.7] (7.87-31.89) 
Eastern Desert Red Sea (5/5) 51/140 [36.4] (28.92-44.66) 
Total 24 (69/71) 162/840 [19.3] (16.76-22.09) 
Buffaloes Western Desert New Valley (6/6) 3/60 [5.0] (1.71-13.70) 
Matrouh (3/3) 2/60 [3.3] (0.92-11.36) 
Nile Valley a. Delta Alexandria (3/3) 2/4 [50.0] (15.00-85.00) 
Beheira (2/2) 1/4 [25.0] (4.56-69.94) 
Cairo (1/1) 0/4 [0.0] (0.00-48.99) 
Damietta (1/1) 0/4 [0.0] (0.00-48.99) 
Dakahlia (1/1) 0/4 [0.0] (0.00-48.99) 
Kafr El Sheikh (2/2) 2/4 [50.0] (15.00-85.00) 
Gharbia (2/2) 2/4 [50.0] (15.00-85.00) 
Sohag (1/1) 0/8 [0.0] (0.00-32.44) 
Ismailia (2/2) 2/4 [50.0] (15.00-85.00) 
Qalyubia (1/1) 1/4 [25.0] (4.56-69.94) 
Menoufia (2/2) 0/4 [0.0] (0.00-48.99) 
Minya (2/2) 0/4 [0.0] (0.00-48.99) 
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Suez (2/2) 0/4 [0.0] (0.00-48.99) 
Sharkia (2/2) 4/4 [100.0] (51.01-100.00) 
Qena (1/1) 1/8 [12.5] (2.24-47.09) 
Port Said (1/1) 0/4 [0.0] (0.00-48.99) 
Luxor (1/1) 0/4 [0.0] (0.00-48.99) 
Giza (2/2) 0/4 [0.0] (0.00-48.99) 
Fayoum (2/2) 3/4 [75.0] (30.06-95.44) 
Beni Suef (2/2) 3/8 [37.5] (13.68-69.43) 
Aswan (3/3) 1/20 [5.0] (0.89-23.61) 
Assuit (2/2) 0/12 [0.0] (0.00-24.25) 
Eastern Desert Red Sea (6/6) 7/60 [11.7] (5.77-22.18) 
Total 25 (53/53) 34/304 [11.2] (8.11-15.22) 
Sheep Western Desert New Valley (4/4) 11/112 [9.8] (5.57-16.73) 
Matrouh (4/4) 8/150 [5.3] (2.73-10.17) 
Nile Valley a. Delta Alexandria (3/3) 0/12 [0.0] (0.00-24.25) 
Beheira (2/2) 2/12 [16.7] (4.70-44.80) 
Cairo (2/2) 1/12 [8.3] (1.49-35.39) 
Damietta (2/2) 3/12 [25.0] (8.89-53.23) 
Dakahlia (2/2) 1/12 [8.3] (1.49-35.39) 
Kafr El Sheikh (3/3) 0/12 [0.0] (0.00-24.25) 
Gharbia (2/2) 0/12 [0.0] (0.00-24.25) 
Sohag (2/2) 2/24 [8.3] (2.32-25.85) 
Ismailia (4/4) 2/12 [16.7] (4.70-44.80) 
Qalyubia (2/2) 1/12 [8.3] (1.49-35.39) 
Menoufia (2/2) 1/12 [8.3] (1.49-35.39) 
Minya (2/2) 1/12 [8.3] (1.49-35.39) 
Suez (2/2) 0/12 [0.0] (0.00-24.25) 
Sharkia (2/2) 2/12 [16.7] (4.70-44.80) 
Qena (3/3) 2/24 [8.3] (2.32-25.85) 
Port Said (2/2) 0/12 [0.0] (0.00-24.25) 
Luxor (0/0) n. a. 
Giza (3/3) 0/12 [0.0] (0.00-24.25) 
Fayoum (2/2) 3/12 [25.0] (8.89-53.23) 
Beni Suef (2/2) 0/24 [0.0] (0.00-13.80) 
Aswan (2/2) 0/14 [0.0] (0.00-21.53) 
Assuit (3/3) 4/36 [11.1] (4.41-25.32) 
Eastern Desert Red Sea (6/6) 20/140 [14.3] (9.44-21.04) 
Total 24 (63/63) 64/716 [8.9] (7.06-11.25) 
Goats Western Desert New Valley (4/4) 1/24 [4.2] (0.74-20.24) 
Matrouh (3/3) 2/24 [8.3] (2.32-25.85) 
Nile Valley a. Delta Alexandria (3/3) 2/12 [16.7] (4.70-44.80) 
Beheira (2/2) 1/12 [8.3] (1.49-35.39) 
Cairo (0/0) n. a. 
Damietta (0/0) n. a. 
Dakahlia (0/0) n. a. 
Kafr El Sheikh (3/3) 1/12 [8.3] (1.49-35.39) 
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Gharbia (2/2) 3/12 [25.0] (8.89-53.23) 
Sohag (1/1) 0/10 [0.0] (0.00-27.75) 
Ismailia (2/2) 5/12 [41.7] (19.33-68.05) 
Qalyubia (2/2) 0/12 [0.0] (0.00-24.25) 
Menoufia (0/0) n. a. 
Minya (2/2) 1/12 [8.3] (1.49-35.39) 
Suez (0/0) n. a. 
Sharkia (2/2) 0/12 [0.0] (0.00-24.25) 
Qena (2/2) 0/24 [0.0] (0.00-13.80) 
Port Said (2/2) 0/12 [0.0] (0.00-24.25) 
Luxor (2/2) 0/12 [0.0] (0.00-24.25) 
Giza (2/2) 0/10 [0.0] (0.00-27.75) 
Fayoum (0/0) n. a. 
Beni Suef (2/2) 3/24 [12.5] (4.34-31.00) 
Aswan (2/2) 1/14 [7.1] (1.27-31.47) 
Assuit (2/2) 0/36 [0.0] (0.00-9.64) 
Eastern Desert Red Sea (4/4) 1/25 [4.0] (0.71-19.54) 
Total 19 (45/45) 21/311 [6.8] (4.46-10.10) 
Camels Western Desert New Valley (6/6) 41/100 [41.0] (31.87-50.80) 
Matrouh (4/4) 37/100 [37.0] (22.78-40.63) 
Nile Valley a. Delta Alexandria (3/3) 1/8 [12.5] (2.24-47.09) 
Beheira (2/2) 6/8 [75.0] (40.93-92.85) 
Cairo (2/2) 4/8 [50.0] (21.52-78.48) 
Damietta (2/2) 2/8 [25.0] (7.15-59.07) 
Dakahlia (2/2) 3/8 [37.5] (13.68-69.43) 
Kafr El Sheikh (3/3) 1/8 [12.5] (2.24-47.09) 
Gharbia (3/3) 3/8 [37.5] (13.68-69.43) 
Sohag (2/2) 7/16 [43.8] (23.10-66.82) 
Ismailia (4/4) 1/8 [12.5] (2.24-47.09) 
Qalyubia (2/2) 2/8 [25.0] (7.15-59.07) 
Menoufia (2/2) 0/8 [0.0] (0.00-32.44) 
Minya (2/2) 1/8 [12.5] (2.24-47.09) 
Suez (2/2) 4/8 [50.0] (21.52-78.48) 
Sharkia (2/2) 3/8 [37.5] (13.68-69.43) 
Qena (3/3) 4/16 [25.0] (10.18-49.50) 
Port Said (2/2) 2/8 [25.0] (7.15-59.07) 
Luxor (2/2) 4/8 [50.0] (21.52-78.48) 
Giza (2/2) 0/8 [0.0] (0.00-32.44) 
Fayoum (2/2) 3/8 [37.5] (13.68-69.43) 
Beni Suef (2/2) 9/16 [56.3] (33.18-76.90) 
Aswan (3/3) 27/40 [67.5] (52.02-79.92) 
Assuit (3/3) 9/24 [37.5] (21.16-57.29) 
Eastern Desert Red Sea (5/5) 41/80 [51.3] (40.49-61.89) 
Total 25 (67/67) 215/528 [40.7] (36.61-44.96) 
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S2 Table. Positive farm animals kept in different animal keeping systems in Egypt. 
n = number. 
 
Animal Species 
Animal Keeping System 
n Serum positive [%] 
pasture 
stationary/ 
stable nomadic missing 
Cattle (n = 840) 6 [0.7] 102 [12.1] 54 [6.4] 0 [0.0] 
Buffaloes (n = 304) 0 [0.0] 25 [8.2] 5 [1.6] 4 [1.3] 
Sheep (n = 716) 8 [1.1] 5 [0.7] 47 [6.6] 4 [0.6] 
Goats (n = 311) 3 [1.0] 0 [0.0] 18 [5.8] 0 [0.0] 
Camels (n = 528) 26 [1.0] 135 [5.0] 318 [11.8] 17 [0.6] 
 
 
S3 Table. Multivariable logistic regression analyses of factors associated with 
seropositivity per animal species. areference (group with lowest risk), aOR = adjusted 
Odds Ratio, CI = confidence interval. 
 
Cattle 
Variable 
Regression 
Coefficient 
Standard 
Error 
Significance aOR 95% CI 
 Domain     <0.0001     
Western Deserta       1.00   
Nile Valley a. 
Delta 
-0.27 0.21 0.200 0.77 0.51-1.15 
Eastern Desert 1.01 0.23 <0.0001 2.75 1.76-4.29 
Constant -1.52 0.14 <0.0001     
 
     
Buffaloes 
Variable 
Regression 
Coefficient 
Standard 
Error 
Significance aOR 95% CI 
 Domain     0.007     
Western Deserta       1.00   
Nile Valley a. 
Delta 
1.61 0.51 0.002 5.01 1.83-13.71 
Eastern Desert 1.11 0.61 0.068 3.04 0.92-10.01 
Constant -3.14 0.46 <0.0001     
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Sheep 
Variable 
Regression 
Coefficient 
Standard 
Error 
Significance aOR 95% CI 
 Domain     0.052     
Western Deserta       1.00   
Nile Valley a. 
Delta 
0.11 0.32 0.725 1.12 0.60-2.08 
Eastern Desert 0.76 0.34 0.026 2.13 1.10-4.14 
Constant -2.55 0.29 <0.0001     
 
     
Goats 
Variable 
Regression 
Coefficient 
Standard 
Error 
Significance aOR 95% CI 
Constant -2.62 0.23 0.073     
 
     
Camels 
Variable 
Regression 
Coefficient 
Standard 
Error 
Significance aOR 95% CI 
Housing     0.002     
othera       1.00   
nomadic 0.86 0.28 0.002 2.37 1.36-4.12 
Age category     0.024     
≤ 4 yearsa       1.00   
> 4 years -0.75 0.33 0.024 0.47 0.25-0.91 
Constant -0.38 0.36 0.290     
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IV DISCUSSION 
1 Assessment of Seroprevalences of Coxiella burnetii-Specific 
Antibodies in Egyptian Livestock 
1.1 Evaluation of Serological Findings of Coxiella burnetii-Specific Antibodies 
Available data on the epidemiology of Q fever in animals of African countries are 
limited although Q fever is a re-emerging zoonotic disease in humans and animals. In 
Egypt, only a few seroprevalence data of Coxiella burnetii-specific antibodies in 
livestock are available and restricted to a few districts [133, 135, 142, 304, 305]. 
Therefore, this nationwide cross-sectional survey was conducted to evaluate the 
prevalence of Cb-specific antibodies among the most important livestock species that 
might serve as natural reservoirs in Egypt: cattle, buffaloes, sheep, goats and camels. 
Further, this study aimed to provide a deeper understanding of the epidemiology of 
Q fever in Egypt presenting a baseline for further research into the public health impact 
of Q fever and implementation of public health intervention. 
 
1.1.1 Seroprevalence Results in Animals 
An overall seroprevalence of Cb-specific antibodies of 18.4% (496/2,699) was found in 
Egyptian livestock. In detail, Cb-specific antibodies were detected in 40.7% of camels 
(215/528), 19.3% of cattle (162/840), 11.2% of buffaloes (34/304), 8.9% of sheep 
(64/716) and 6.8% of goats (21/311). The high seroprevalence results of camels and 
cattle found were reflected in the high odds for seropositivity for cattle (aOR: 3.17; 95% 
CI: 1.96-5.13) and camels (aOR: 9.75; 95% CI: 6.02-15.78) of the multivariable 
analysis. Comparable studies about Cb-specific antibodies in Egypt or bordering 
countries do not exist (Tab. A1). This study was conducted with a reliable study design, 
a probabilistic sampling approach and a representative sample size, except for goats. 
Comparisons with other Egyptian studies could only be realized by calculating the 
seroprevalence for the governorates in question. Especially the results for small 
governorates in the Nile Valley and Delta Area should not be considered itself because 
the study is based on three classified domains. Hence these results, often calculated 
from two farms for each animal species, were not representative for a small 
governorate. This is supported by the wide ranges of the seroprevalence results for each 
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animal species determined for each governorate and village of this study. 
Nevertheless, the overall results of Egypt and each domain indicate that Q fever is 
endemic throughout Egypt. Camels and buffaloes stand out as reservoir for Cb besides 
cattle. However, only the presence of antibodies was detected indicating a prior contact 
to the pathogen. Hence, further research should concentrate on detection of Cb to assess 
infection risk and public health impact. 
 
1.1.2 Seropositivity of Animals Correlated to Specific Risk Factors 
Besides the risk factor “animal species”, “geographical location” was associated with 
seropositivity in livestock (Fig. A7-A9). Several studies identified risk factors like high 
wind speed, dry and hot climate and open landscapes facilitating Cb spreading and 
increasing infection risk for humans and animals [17, 178, 179]. In this study, landscape 
conditions were taken in consideration in so far as Egypt was divided into three 
domains. The Western Desert Domain mainly consist of desert whereas the Nile Valley 
and Delta Area is, corresponding to Egyptian conditions, more or less green land. The 
Eastern Desert Area is dry but has mountain-like ranges and is bordering the Red Sea. 
In the Eastern Desert Area seroprevalence in cattle, sheep and camels was higher 
compared to those in the other domains. The final logistic regression associated 
seropositivity with animals from the Eastern Desert Area (aOR: 2.16; 95% CI: 1.62-
2.88). These findings may be explained by the missing samples from the Sinai that 
could not be collected due to ongoing political instabilities and security risks. The lower 
number of samples may cause a bias. In contrast, the results for buffaloes and goats 
were highest in the Nile Valley and Delta Area. A scientific explanation for these 
findings could not be found. Therefore, future studies should focus on causes for the 
risk factor “geographical location” and specify them. 
In this study, animal husbandry system, as well as the age and the origin of an animal 
were no potential risks in the multivariable risk factor analysis. The seroprevalence 
results for animal husbandry system and age, however, were statistically significant 
(p = 0.002, p < 0.001). A classification of husbandry systems to identify a risk factor for 
Cb is not useful in Egypt and possibly other countries. This finding may be explained 
by the dissemination of Cb via wind and the open construction of stables in Egypt. 
Stables are constructed of fences and open roofs also allowing Cb spreading through 
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wind. Most positive animals, however, are kept nomadic (318/496 [64.1%]). Maybe, 
environmental contamination is higher because excretions of the animals were not 
removed and the same paths were used for animal ranging. Widespread distribution of 
aerosols contaminated with Cb and thus an increase of risk of infection for animals and 
humans may be the results. 
In general, it is not known if a specific age of animal is correlated to seropositivity of 
Cb. Therefore, seroprevalences depending on the age of animals was calculated in this 
study to be 11.0% (107/970) in ≤4-year-old and 22.5% (389/1729) in >4-year-old 
animals. It is, however, more reasonable to consider each animal species itself due to 
their specific characteristics, e.g. life expectation or type of use (Tab. 1). In 
consequence of the very limited data available about this specific issue, comparison 
with other study results is restricted. No research is available for Egypt and to the best 
knowledge of the author, only one study is available from an African country. 
Investigations with the same ELISA used in this study in small ruminants (goats and 
sheep) in the Gambia showed that 10% (n = 256) of <1 year-, 26% (n = 379) of 
1-3-year- and 27% (n = 244) of ≥4-year-old animals had Cb-specific antibodies [306]. 
In Egypt, most small ruminants with a positive antibody result were between two and 
four years old (Tab. 1). This finding may be explained by the fact that most small 
ruminants sampled were younger than four years. It is not clarified if most small 
ruminants older than four years served for meat production and thus were not available 
for sampling. Sampling was done without consideration of animal age. Additionally, it 
is suggested that age of animals was often only estimated by the animal owner which 
makes a classification and thus realistic comparison difficult. On the other hand, the 
number of positive animals compared to the number of animals sampled is too low to 
point out a fundamental statement. A clearer figure is shown by the seroprevalence 
results in camels and cattle. The majority of positive tested animals of these species 
were older than four years. While no comparable data are available for camels, Böttcher 
et al. investigated 3,965 cattle from 105 farms in Bavaria with the same ELISA used in 
this survey. Seroprevalence results of 5% in 1-2-year-, 15% in 2-3-year- and 25-30% in 
≥4-year-old cattle were obtained [274]. These results support the findings that 
seroprevalence in cattle >4 years of age shows a plateau and is higher than in younger 
animals. This comparison is hampered by the fact that the conditions in both countries 
are different, e.g. husbandry system, climate and landscape. Furthermore, the immune 
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system and hence the immune status of each group of age play an important role, not 
only in cattle. In that study, it was suggested that cattle younger than one year of age 
showed a positive ELISA due to maternally received antibodies [274]. In general, 
animals younger than 1.5 years were not sampled in this survey to avoid maternal 
antibody cross reactions. Maternal antibodies might explain the positive reactivity to 
PhII but transient infection could not be excluded [274]. Interestingly, Böttcher et al. 
found that PhI-/PhII+ 1-2-year-old heifers frequently seroconverted to negative, whereas 
primiparous cows with the same pattern changed to negative, PhI and PhII positive or 
stayed PhI-/PhII+ (persistent) equally [274]. These findings give new insights into the 
probable systemic immunotolerance to and subsequent persistence of Q fever infection 
but have to be determined further on for each animal species. 
Table 1. Numbers of seropositive Egyptian livestock correlated to their estimated 
age. 
Animal Species Estimated Animal Age (years) 
n 2-3 3-4 4-5 5-6 6-7 7-8 8-9 
Cattle  (n = 162) 6 7 51 34 45 12 7 
Buffaloes (n = 34) 3 0 3 7 9 8 4 
Sheep  (n = 64) 24 26 13 1 0 0 0 
Goats  (n = 21) 7 10 4 0 0 0 0 
Camels  (n = 215) 8 16 34 57 72 23 5 
Total  (n = 496) 
48 59 105 99 126 43 16 
9.7% 11.9% 21.2% 20.0% 25.4% 8.7% 3.2% 
n = number of animals tested seropositive 
 
1.1.3 Possible Effects and Evaluation of the ELISA Test Used 
The IDEXX ELISA Checkit was applied in this study. Milk, blood and serum 
specimens from cattle, sheep and goats can be used as samples. The manufacturer states 
a 100% specificity and sensitivity compared to CFT by analyzing serum samples of 
field and experimentally infected goats [307]. Several studies, however, question the 
efficiency, especially the sensitivity of this ELISA [273, 274, 277, 284]. Additionally, 
this ELISA is used for routine testing samples of buffaloes and camels although it is not 
authorized for these animal species. Therefore, the discussion about the evaluation of 
this ELISA and its possible statistical effect is indispensable. 
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Sensitivity of commercially available ELISAs may be affected by the Cb whole cell 
antigen used. The ELISA used is based on Cb PhI and II purified whole cell antigens of 
the Nine Mile strain (isolated from ticks) and detects total IgG. It has been demonstrated 
that an ELISA using an ovine strain had the best overall performance compared to those 
using a bovine and a tick one [277]. Whereas Emery et al. did not notice a significant 
increase in sensitivity [308]. A lower sensitivity may also be caused by the lack of IgM 
detection and the missing differentiation between PhI and PhII specific antibodies [273, 
274, 309, 310]. Additionally, it has been shown that a PhI and PhII mixed ELISA is 
insufficient in detecting the PhII-specific response that is associated to IgM class [101, 
274]. 
This ELISA seems to be specific enough for its use in veterinary medicine [247, 310]. 
No cross reactions were recognized testing samples of Chlamydia abortus infected 
sheep when ovine derived Cb antigens were used [277]. It is noteworthy, that IFAs used 
in human medicine showed cross reactions with samples of patients infected with e.g. 
Legionella spp. (micro IFA) and Bartonella spp. (indirect IFA) although they had low 
titers and misdiagnosis should be improbable [311, 312]. 
Several studies were conducted on Q fever in buffaloes and camels by using IDEXX 
ELISA, suggesting a wide acceptance of application for buffalo and camel samples 
[104, 133, 139, 305, 313, 314]. As mentioned, this assay is not authorized for samples 
of these animals. Phylogenetic relationship of buffaloes and cattle enables the plausible 
use of this ELISA in buffaloes [315]. For camel samples, Kittelberger et al. recommend 
the use of complement fixation tests (CFTs) due to the missing evaluation of the 
ELISAs [275]. However, in this survey detection of Cb-specific antibodies in serum 
samples of camelids using the conjugated anti-ruminant antibodies was successful (Fig. 
A1). Surprisingly, the dilution ratio given by the manufacturer could be maintained. 
Nevertheless, it has never been proven that this test is valid for samples of the animals 
in question and no cutoffs were determined. 
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A cutoff value with an optical density (OD) of ≥40% is recommended by the 
manufacturer and the World Health Organization (WHO) for blood and milk samples, 
although Paul et al. calculated that no cutoff would be analytically perfect [310]. There 
will always be false positive and false negative results due to pipetting inaccuracy or 
possible cross reactions. Diagrams of the obtained OD results were created 
(Fig. A2-A6). In general, progression (hypothetical frequent distribution) should show a 
peak before the given negative (OD <30%) and after the given positive (OD ≥40%) 
cutoff for this indirect ELISA. The percentage of false results acceptable for a 
diagnostic application should be the basis for the chosen cutoffs (Fig. 6) [316]. Thus, 
sensitivity and specificity play an important role. 
 
Figure 6. Determination of possible cutoffs for an indirect ELISA. 
Cited from Wright et al., 1993. 
Samples from animals out of a healthy and an infected group should be investigated to 
obtain a hypothetical frequency distribution. The acceptable percentage of false positive 
and false negative determine the cutoffs, that should be chosen, the sensitivity and 
specificity. 
PP = percent positivity 
 
The obtained diagrams (Fig. A2-A6) show a similar distribution of the obtained OD 
values in cattle, sheep and goats. It is interesting, that the OD distribution in buffaloes 
(Fig. A3) is similar to that in cattle (Fig. A2), although less animals were investigated. 
The second peak determining the positive cutoff for buffaloes, however, is visible in the 
diagram at an OD value of 60% only and not at an OD value of 40% as usual in e.g. 
cattle. This finding and the high determined numbers of negative buffaloes might be 
explained by the hypothesis that buffaloes are not as susceptible to Cb infection as cattle 
and thus the immune response may not be strong. Furthermore, it might be possible that 
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Cb-specific antibodies of buffaloes are not as sensitive to the Nine Mile derived antigen 
and tests should be repeated with a bovine or ovine derived antigen to reveal false 
negative results. The diagram of camel samples also shows two peaks, but the equivocal 
area (OD 30-39.99%) includes more samples than seen in the other animal species 
(Fig. A6). Additionally, antibody response reactivity seems to be higher. This finding 
might be explained by the specific antibody structure of camelidae. Their immune 
system also produces antibodies with heavy chains only, besides conventional 
antibodies with heavy and light chains [317]. It has been shown that those antibodies 
have a specific extended structural feature suggesting that this allows and supports 
affinity to specific antigen structures when conventional antibodies fail [318]. Thus, 
false positive results cannot be excluded. In conclusion, the diagrams show that cutoffs 
for camel and buffalo samples should be reconsidered and the use of the IDEXX ELISA 
in these animal species has to be validated. Validation is hampered by the fact, that 
“true” negative (uninfected) and “true” positive (infected) animals are necessary to 
determine the exact cutoffs. As mentioned, animals with a seronegative status may also 
be Cb shedders. Lack of phase specific assays disallow antibody detection in samples 
taken from an animal during the early stage of infection [319]. Likewise, no further 
sampling was done to assess delayed antibody responses in this survey. Thus, it is likely 
that not all seropositive animals were detected. 
 
 
1.2 Milk Samples 
In general, milk samples have some advantages regarding animal welfare and personnel 
occupational safety as collection of milk is easy, non-invasive and not as stressful as 
blood sampling for (dairy) animals. Additionally, it is very cost efficient as DNA of Cb 
or Cb-specific antibodies can be investigated in bulk tank milk (BTM) samples 
detecting Q fever at herd level [239, 272]. Comparison of milk and blood ELISA 
analysis showed a negligible higher sensitivity of milk samples (0.86 to 0.84) in dairy 
cattle [310]. This finding was confirmed by Rodolakis et al. [155]. Specificity was 0.99 
[310]. Therefore, investigation of BTM is a useful tool for surveillance programs in 
dairy farms. For non-lactating cows, young and male animals, nevertheless, blood 
sampling is still needed. 
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However, the use of serological methods to detect antibodies in milk and the obtained 
results are controversially discussed. It is not clear, if detected antibodies are produced 
due to systemic or local Q fever infection. If Cb-specific antibodies result from systemic 
infection, they have penetrated the blood-udder barrier. In general, penetration of the 
blood-udder barrier in bovines is a physiological process. Maternal antibodies 
accumulate in the mammary gland and the resulting colostrum ensures immune defense 
and thus promotes survival of the calf. Antibodies may also be excreted locally, if the 
mammary gland is infected only. It is also not clear if only parts of the mammary gland 
or the whole udder can be infected, because of the different anatomic structure in 
different animal species. Clear is, that Cb was detected in experimentally infected 
pregnant goats in the udder and mammary lymph node as well as it can be isolated from 
dairy cattle udders [8, 145]. It has been shown that Cb shedding in milk may be 
intermittent and may last for a longer period of time affecting antibody synthesis. 
Muskens et al. showed that out of 341 BTM samples that correspond to the number of 
tested dairy cattle herds in the Netherlands, most samples were ELISA positive but had 
negative (n = 81, 24%) or positive (n = 76, 22%) PCR result. Whereas the number of 
PCR positive animals rose in the second sampling round [272]. 
During this survey, milk samples from selected blood donors (n = 188) were collected 
and investigated with the IDEXX ELISA, additionally (Tab. 2). 
Table 2. Correlation of the milk and serum ELISA results (paired samples) of 
selected animals (n = 188). 
Animal 
Species 
ELISA results - serum/milk 
n 
Total  
milk 
positive 
Total 
serum 
positive 
Total 
antibody 
positive 
Kappa 
value 
pos/pos pos/neg neg/pos neg/neg n [%] n [%] n [%] 
Cattle 7 7 17 37 24 [12.8] 14 [7.5] 31 [16.5] 0.15 
Buffaloes 1 0 4 6 5 [2.7] 1 [0.5] 5 [2.7] 0.21 
Sheep 1 3 9 18 10 [5.3] 4 [2.1] 13 [6.9] -0.05 
Goats 3 0 5 18 8 [4.3] 5 [2.7] 8 [4.3] 0.45 
Camels 18 4 27 3 45 [23.9] 22 [11.7] 49 [26.1] -0.07 
Total n 
[%] 
30 
[16.0] 
14 
[7.4] 
62 
[33.0] 
82 
[43.6] 
92 
[48.9] 
44 
[23.4] 
106 
[56.4] 
0.18 
n = number of animals tested, pos = positive, neg = negative 
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No data are available about detection of Cb-specific antibodies in milk samples of 
animals from Egypt and only few studies dealt with detection of DNA in dairy cattle 
milk samples. Surprisingly, the findings (Tab. 2) show that one third of the animals had 
blood serum negative and milk positive ELISA results, especially cattle and camels. 
Hence, it is not possible to decide if all these animals had a previous exposure to Cb or 
if they had an actual Q fever infection nor if these antibodies were synthesized locally 
only. In a recent survey about Q fever in dairy cattle most sample pairs were positive 
(n = 249) or negative (n = 176) whereas only few had differing ELISA results [320]. 
Those findings were explained by assumed local antibody production in milk positive 
and serum negative sample animals (n = 8) with low titers, as well as by possible 
disturbance of the antibody transport from blood to milk or low antibody levels in pairs 
with serum positive and milk negative results (n = 15) [320]. In this study, kappa value 
calculations showed only little agreement in paired samples from Egyptian livestock 
except for goats (Tab. 2). In contrast, Guatteo et al. reported high agreement 
(Kappa = 0.89) between milk and blood ELISA of dairy cattle samples [320]. 
Differences might be explained by the fact, that their samples were investigated with an 
ELISA (LSI) based on ovine derived antigen. Further investigations e.g. PCR analysis 
and evaluations of the obtained OD values will be needed to assess possible correlations 
regarding Cb shedding in milk and antibody response. 
 
 
1.3 Conclusion 
In summary, the Cb-specific antibody seroprevalence results of each domain indicate 
that Q fever is endemic throughout Egypt, especially in cattle, buffaloes and camels. 
The only risk factors identified correlating to seropositivity are type of animal species 
and geographical location. Besides cattle, especially camels come to the fore as possible 
reservoir for Cb due to a high seroprevalence. It has to be determined, which effect the 
age and thus maybe the immune status of an animal has on seroprevalence in each 
animal species. Specific conditions such as animal population, climate and physical 
surface characteristics should be evaluated for each domain (geographical location) to 
identify possible risk factors facilitating Cb spreading. Whereas animal husbandry 
systems could be excluded as a risk factor in Egypt. 
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This study showed that many farm animals had previous contact to Cb or actually 
suffered from Q fever when sampled due to a positive antibody result. Future research, 
however, is needed to determine exact cutoff values especially for buffaloes and camels 
for the ELISA test used to avoid false results. Further, phase specific tests may be 
helpful to distinguish current and previous infections. Nevertheless, to identify Q fever 
shedders serology is not useful and combined investigation techniques are needed [158, 
163, 321]. Additionally, other test materials such as milk or birth products should be 
considered besides blood samples. The evaluation of the presence of Cb in the field may 
finally help to give a new insight into the epidemiology of Q fever in Egypt and to 
assess infection risk and public health impact. 
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2 Socioeconomic Burden 
“Socioeconomic burden” is defined as impact of a disease on social and economic 
factors and the combined influence of both. Little is known about the socioeconomic 
burden of Q fever in African countries and only one study in Egypt tried to analyze the 
impact on public health but failed [146]. It has been shown that Q fever infections in 
animals, particularly in livestock, have severe impacts on a country’s economy [322-
324]. Livestock productivity is affected due to abortion epidemics in small ruminants 
leading to animal losses and thus affecting milk, meat and wool production. Further, an 
impact on the public sector is indispensable. Therefore, this study was conducted to give 
an initial assessment with the obtained seroprevalences of Cb-specific antibodies in 
Egyptian livestock concerning the present of Cb and thus the infection risk for humans 
and animals. In addition, animal owners were asked about their consumption of raw 
milk and their general knowledge on Q fever. The latter included transmission, clinical 
signs in animals and application of countermeasures to reduce risk of infection. The 
obtained data may provide a baseline for further research into the public health impact 
of Q fever and implementation of public health intervention.  
The high seroprevalences in this study indicate that Q fever is endemic throughout 
Egypt. It is very likely that Cb is present in many regions. Especially in the Nile Valley 
and Delta Area and Eastern Desert Area it should be reckoned with a high infection 
risk for humans and animals due to a high animal population and the expanding 
economy. Further, tourism in these areas is a flourishing industry. In general, true 
impact on individual income is uncertain, but may be disastrous especially for farmers 
in resource-limited areas in African countries [322, 323]. Thirty thousand euros (0.04% 
of costs incurred in livestock sector) for all farms were calculated for production losses 
on infected farm animals during the big Dutch Q fever outbreak only [324]. Most costs 
(85 Million Euro/outbreak) were caused by the intervention program e.g. organization 
(58%), culling of infected animals (22%), breeding prohibition (14%) and vaccination 
(6%) [324]. It was hypothesized, however, that native Egyptian breeds might show 
infection tolerance to a certain extent as it was assumed that subclinical infections occur 
in Egyptian dairy animals mainly and abortions play a less prominent role. This 
hypothesis was justified by a single observation only: DNA of Cb was detected in the 
placental cotyledons and vaginal discharge of one goat out of 108 animals (26 cattle, 26 
buffaloes, 27 sheep, 29 goats) after abortion [146]. The high seroprevalence numbers in 
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this survey contradict this assumption: Cb-specific antibodies were detected in 40.7% of 
camels, 19.3% of cattle, 11.2% of buffaloes, 8.9% of sheep and 6.8% of goats. These 
findings indicate that Egyptian livestock is susceptible to Cb. Only the low OD values 
in buffaloes might support the suggestion that these animals are not as susceptible to Cb 
infection or they simply do not show an immune response as strong as other animal 
species (Fig. A3). Further research should deal with comparing the sensitivity of 
ELISAs using an ovine and bovine strain for buffalo samples to answer this question. A 
further argument against the hypothesis of infection tolerance is that e.g. high-yield 
dairy cattle have been imported from Europe, especially Germany, and replace local 
breeds partially to increase milk production. 
Import of animals with unknown health status has come to the fore in this study. 
Biosafety in Egypt is lacking. Thus, a (maybe illegal) high import rate with no control 
may have an impact on transmission of Cb. Interestingly, the only animal species found 
to be imported to Egypt were camels with origin in Sudan. Cb-specific antibodies were 
found in 42.1% of imported camels. Whether positive tested camels had contact with Cb 
prior or after import could not be shown. This study, however, supported the 
assumption that high seroprevalences in areas bordering Sudan are correlated to the 
import of infected camels (Fig. A6) [314]. 
Import or uncontrolled animal movement involves the risk of disease spread. Thus, 
infection risk is increased for animals as well as for humans. Although pets, equines or 
pigeons were not sampled in this survey, most Egyptian farmers keep those susceptible 
animal species on their farm additionally (data not shown). Their role in spreading of 
Cb is still not clear but infected animals may be a risk and thus may increase the risk of 
infection of people as well. A study in Egypt showed that the seroprevalence in farmers 
(30.8% [8/26]) was higher than that in veterinarians and their assistances (9.4% [3/32]). 
The difference was explained by the rural residence of the farmers in an area with high 
sheep and goat populations [146]. Interestingly, Abdel-Moein et al. assumed that only 
goats suffer from abortions, although prevalence is low [146]. Retrospective analyses of 
the Dutch Q fever outbreak showed a correlation between decrease in human Q fever 
cases and abortion storms in small ruminants. They showed that the number of human 
cases may be limited in time and the influence of contamination of environment may 
not induce an increase of the number of infections for a longer period of time [103]. 
Nevertheless, during the Q fever outbreak in the Netherlands between 2007-2011, the 
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total loss of the public sector was calculated to be 222 million Euro [324]. The number 
of chronic Q fever patients was high. Surprisingly, treatment costs were calculated to be 
low (<2% of the public health costs). The highest financial impact of public health costs 
was the loss in income due to chronic Q fever infection (34% of the public health costs). 
During long periods of sick leave, the losses accumulate over time especially in cases of 
chronic fatigue syndrome (63% of the public health costs) [324]. In African countries 
manpower is substantial especially for the agricultural sector. Unawareness of 
physicians, misdiagnoses and missing diagnostics in African countries influence the 
impact of Q fever on public health [134]. In a survey in Egypt (2011), Q fever was often 
not considered as differential diagnostic in hospitalized FUO cases although infections 
(42% [39/93]) were the most common cause headed by brucellosis (8/39) and infective 
endocarditis (6/39) [325]. Endocarditis is one of the most important sequelae of Q fever. 
These findings might influence public health as well as the agricultural sector 
enormously. 
Socioeconomic assessment of individual Q fever cases and outbreaks is not easy even in 
developed countries. Obvious is that financial resources in third world countries are not 
available to establish sound diagnostic laboratories or to conduct solid research. 
Additionally, physicians, veterinarians and farmers are often unaware of the clinical 
manifestations of Q fever, spreading ways and risk factors facilitating dissemination of 
Cb. This study showed that none of the animal owners interviewed had any knowledge 
on Q fever or about any application of countermeasures like removing birth products. 
Further, 8.7% of animal owners reported to consume raw camel milk regularly. These 
findings, the lack in biosafety measures and the high seroprevalence found in the 
Egyptian livestock point out that Q fever most likely is a problem in Egypt. The 
problem and the far-reaching consequences, however, seem to be still unknown so far. 
The impact of this disease might be eminent for the economy, humans and animal 
populations. Therefore, further studies combining direct and indirect diagnostic 
techniques are needed to assess the presence of Cb and its true impact on Egyptian 
livestock. Changes in and development of animal husbandry and rising populations, 
solid public knowledge, efficient diagnostics and ongoing research are needed to 
implement intervention programs to contain Q fever spreading and disease burden. 
Therefore, first world countries have an important responsibility in contributing to set 
up laboratories, to provide awareness-rising measures and to develop cost-efficient 
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Q fever diagnostics. The conducted survey is also part of a German Partnership 
Program for Excellence in Biological and Health Security funded by the German 
Foreign Office, which intends to set up laboratories and awareness-rising measures e.g. 
training programs in Egypt to raise biosafety. 
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V SUMMARY 
Coxiella burnetii (Cb) is an obligate intracellular bacterium and the causative agent of 
Q fever in humans and animals. The pathogen is classified as a category B biological 
agent and has a high socioeconomic burden as seen during the last big Q fever outbreak 
in the Netherlands. Little is known about the socioeconomic burden in Egypt and other 
African countries in general. Only limited data on the epidemiology of Q fever in 
Egyptian livestock are available and are restricted to few districts although Egypt has 
risk factors favoring spreading, persistence and transmission of Cb. Therefore, the 
objectives of this survey were to estimate the seroprevelance of Cb in cattle, buffaloes, 
sheep, goats and camels. Additionally, possible risk factors were identified by 
association with seropositivity in Egypt. The obtained data should build a solid basis for 
further interventions involving improvement of public health countermeasures and 
animal welfare in Egypt to contain risk of infection. Additionally, this survey may 
provide information for further African countries and future studies in risk factors. 
Basis of this study was a solid epidemiological calculation of the size of test specimen 
using the two stage sampling method to evaluate the seroprevalence in the three 
domains of Egypt (Western Desert Area, Nile Valley and Delta Area and Eastern 
Desert Area). This method was used, because no actual data on animal populations nor 
animal data bases were available. Additionally, unequal distribution of animal 
populations was suggested due to the different agro-ecological zones (gegraphical 
characteristics, climate and water availability). Blood samples of the most important 
livestock animal species in Egypt were collected: cattle, buffaloes, sheep, goats and 
camels. A questionnaire was used to assess the origin of animals, animal keeping 
system and animal age. Additionally, personal details about knowledge on Q fever of 
the owner and consumption of raw milk were asked. Serum samples were investigated 
with a commercially available ELISA (IDEXX CHEKIT Q fever Antibody ELISA Test 
Kit, IDEXX Laboratories, Switzerland). The overall seroprevalence was 18.4% 
(496/2,699). Cb-specific antibodies were detected in 40.7% of camels (215/528), 19.3% 
of cattle (162/840), 11.2% of buffaloes (34/304), 8.9% of sheep (64/716) and 6.8% of 
goats (21/311) indicating that Q fever is endemic in Egypt. Animal species was 
identified as risk factor for seropositivity. Especially camels come to the fore as 
possible reservoir for Cb. The seroprevalence results for cattle, sheep and camels were 
highest in the Eastern Desert Area, those of goats and buffaloes in the Nile Valley and 
Delta Area. The geographical location was identified as second risk factor (Eastern 
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Desert Area, aOR: 2.16; 95% CI: 1.62-2.88). Future studies, however, should focus on 
cause for and specify the risk factor “geographical location”. The origin of and the age 
of an animal and animal keeping system were not correlated to seropositivity. The 
results for animal age and animal keeping systems were statistically significant. 
Stationary animal husbandry is common in Egypt showing changes in and development 
of animal husbandry systems. Nomadic animal keeping, however, is still the leading 
husbandry system for this agricultural country. Both systems lead to the suggestion that 
spreading of Cb is high, although excretion of the organism was not investigated. To 
assess excretion, spreading and impact on animal health further surveys have to be 
conducted with combined diagnostic techniques. 
It has been shown that comparison with other serological surveys was difficult due to 
missing sampling schemes, differences in serological diagnostic methods (and cutoffs), 
low numbers of test specimen and partly regional sampling. Drawbacks such as lack in 
PhII reactivity (detection of early stage of infection) of the used ELISA are discussed, 
although this assay has a high sensitivity and specificity. The use of the IDEXX ELISA 
for samples of buffaloes and especially for camels, however, has to be further evaluated 
to avoid false results as the distribution of the OD values are different to those of the 
other animal species analyzed. Final validation is lacking. Thus, development strategies 
for new diagnostic techniques are indispensable. 
At present, eradication of Q fever seems impossible. Therefore, elucidation and 
performances of training courses may help to raise awareness about the epidemiology of 
Q fever and correlated risk factors. This survey showed that no animal keeper 
interviewed has any knowledge on Q fever at all. Few animal keepers consumed raw 
camel milk showing their unawareness also. Nevertheless, further investigations would 
be needed to assess impact on the economy and public health as well as to show 
prevalence of Q fever as cause of FUO in humans in Egypt. 
In summary, this nationwide epidemiological study in ruminants and camels highlights 
that the prevalence of Coxiella burnetii-specific antibodies is high in Egyptian livestock 
but the disease is neglected, although risk for transmission and human infection is high. 
Further studies are needed to provide meaningful data on the epidemiology of Q fever 
in Egypt and other African countries. Help and support from abroad is needed to contain 
Q fever dissemination with intervention programs and to raise awareness to improve 
public health countermeasures and animal welfare. 
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VI ZUSAMMENFASSUNG 
Coxiella burnetii (Cb) ist ein obligat intrazelluläres Bakterium und Erreger des 
Q-Fiebers bei Menschen und Tieren. Das Pathogen ist in der Kategorie B der 
biologischen Wirkstoffe eingegliedert und birgt, wie man es während des letzten großen 
Q-Fieber Ausbruchs in den Niederlanden gesehen hat, eine hohe soziökonomische 
Belastung. Über die soziökonomische Belastung in Ägypten, wie auch generell in 
afrikanischen Ländern, ist wenig bekannt. Nur wenige epidemiologische Daten, zudem 
noch begrenzt auf wenige Distrikte, sind für Q-Fieber im ägyptischen Nutztierbestand 
vorhanden, obwohl in Ägypten einige Risikofaktoren erfüllt sind, die die Verbreitung, 
Persistenz und Übertragung von Cb begünstigen. Deshalb waren die Ziele dieser Studie, 
die Seroprävalenz von Cb spezifischen Antikörpern bei Rindern, Büffeln, Schafen, 
Ziegen und Kamelen einzuschätzen. Zusätzlich wurden Risikofaktoren in Ägypten 
identifiziert, die mit einem seropositiven Ergebnis assoziiert wurden. Die erhaltenen 
Daten sollten weiterhin eine solide Basis für weitere Interventionen bilden, die 
Gegenmaßnahmen für die öffentliche Gesundheit und Tiergesundheit involvieren, um 
das Infektionsrisiko einzudämmen. Zusätzlich stellt diese Untersuchung Informationen 
für weitere afrikanische Länder und zukünftige Studien über Risikofaktoren bereit. 
Eine solide epidemiologische Berechnung der Probengröße mittels der 
Two-Stage-Methode war Basis dieser Studie, um die Seroprävalenz in den drei 
Gebieten Ägyptens (Western Desert Area, Nile Valley and Delta Area und Eastern 
Desert Area) zu evaluieren. Die genutzte Methode musste angewendet werden, da keine 
aktuellen Daten über die Tierpopulation und Tierdatenbanken zur Verfügung standen. 
Zudem wurde eine ungleiche Verteilung der Tierpopulation aufgrund der verschiedenen 
agroökologischen Zonen (Oberflächenbeschaffenheit, Klima und Wasserverfügbarkeit) 
angenommen. Blutproben wurden von den wichtigsten Nutztierarten in Ägypten 
gesammelt: Rinder, Büffel, Schafe, Ziegen und Kamele. Mittels eines Fragebogens 
wurden Daten zur Herkunft des Tieres, dem Tierhaltungssystem und dem Tieralter 
gesammelt. Zusätzlich wurden persönliche Daten über das Wissen zu Q-Fieber und den 
Konsum von Rohmilch abgefragt. Die Serumproben wurden mit einem kommerziell 
erwerblichen ELISA (IDEXX CHEKIT Q-Fieber Antikörper ELISA Test Kit, IDEXX 
Laboratories, Schweiz) untersucht. Die Seroprävalenzergebnisse beliefen sich auf 
18,4% (496/2.699). Cb spezifische Antikörper wurden in 40,7% der Kamele (215/528), 
19,3% der Rinder (162/840), 11,2% der Büffel (34/304), 8,9% der Schafe (64/716) und 
6,8% der Ziegen (21/311) detektiert, und lassen die Annahme zu, dass Q-Fieber in 
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Ägypten endemisch ist. Die Tierart wurde als Risikofaktor für Seropositivität 
identifiziert. Vor allem Kamele rücken in den Fokus als mögliche Reservoire für Cb. 
Die Seroprävalenzergebnisse von Rindern, Schafen und Kamelen waren am höchsten in 
der Eastern Desert Area, die von Ziegen und Büffeln dagegen in der Nile Valley and 
Delta Area. Als zweiter Risikofaktor wurde die geografische Lage identifiziert (Eastern 
Desert Area, aOR: 2.16; 95% CI: 1.62-2.88). Zukünftige Studien sollten jedoch den 
Fokus auf die Ursache für die geografische Lage legen und diese spezifizieren. Die 
Herkunft und das Alter eines Tieres als auch das Haltungssystem wurden nicht mit der 
Seropositivität korreliert. Die Ergebnisse für das Alter und das Haltungssystem waren 
jedoch statistisch signifikant. Das stationäre Haltungssystem in Ägypten ist sehr gängig 
und zeigt die Veränderung und Weiterentwicklung in den Tierhaltungssystemen. 
Nichtsdestotrotz ist die nomadische Haltung führend für dieses agrikulturelle Land. 
Beide Haltungssysteme führen zu der Annahme, dass die Verbreitung von Cb sehr hoch 
ist, obwohl die Exkretion des Erregers nicht untersucht wurde. Weitere Studien, 
ausgeführt mit kombinierten Untersuchungsmethoden, wären nötig, um die 
Ausscheidung, die Verteilung und den Einfluss auf die Tiergesundheit zu beurteilen. 
Der Vergleich mit anderen Seroprävalenzstudien gestaltete sich als schwierig, da dort 
Stichprobenpläne fehlten, andere serologische Diagnostikmethoden (und Cutoffs) 
angewandt wurden, die Probengröße zu klein war und teilweise örtlich begrenzt beprobt 
wurde. Die Nachteile des benutzten ELISAs, z. B. die fehlende Reaktion mit PhII 
Antigen (Erkennung des frühen Infektionsstadiums) werden in dieser Arbeit diskutiert, 
obwohl er eine hohe Sensitivität und Spezifität hat. Die Anwendung des IDEXX 
ELISAs bei Büffel- und vor allem Kamelproben sollte jedoch weiter evaluiert werden, 
um falsche Ergebnisse zu vermeiden, da die Verteilung der Werte der optischen Dichte 
nicht die gleiche ist wie bei den anderen untersuchten Tierspezies. Im Allgemeinen 
weist die Validierung Mängel auf. Deshalb sind Entwicklungsstrategien für neue 
Diagnosetechniken unabdingbar. 
Zurzeit erscheint die Ausmerzung von Q-Fieber unmöglich, weshalb Aufklärung und 
Durchführungen von Schulungen helfen können, das Bewusstsein über die 
Epidemiologie von Q-Fieber und dessen Risikofaktoren zu erhöhen. Diese Studie 
zeigte, dass alle befragten Tierbesitzer kein Wissen über Q-Fieber besaßen. Die 
Unwissenheit zeigte sich ebenso dadurch, dass Tierbesitzer Rohmilch von Kamelen 
verzehren. Dennoch sind weitere Untersuchungen nötig, um den Einfluss auf die 
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Wirtschaft und die öffentliche Gesundheit, als auch die Prävalenz von Q-Fieber als 
Ursache für Fälle mit Fieber ungeklärten Ursprungs in Ägypten zu beurteilen. 
Zusammenfassend hebt diese landesweite epidemiologische Studie in Wiederkäuern 
und Kamelen hervor, dass die Prävalenz von Coxiella burnetii spezifischen Antikörpern 
in ägyptischen Nutztieren hoch ist, die Krankheit jedoch vernachlässigt wird, obwohl 
das Übertragungs- und Infektionsrisiko für Menschen ebenfalls hoch ist. Weitere 
Studien werden benötigt, um aussagekräftige Daten über die Epidemiologie von 
Q-Fieber in Ägypten und anderen afrikanischen Ländern zur Verfügung zu stellen. Hilfe 
und Unterstützung von außen sind nötig, um die Verbreitung von Q-Fieber mit 
Interventionsprogrammen einzudämmen, das Bewusstsein zu erhöhen und somit 
Gegenmaßnahmen im Sinne der Gesundheit für Mensch und Tier zu verbessern. 
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VIII APPENDIX 
Table A1. Seroprevalences of Coxiella burnetii-specific antibodies in serum samples from humans and animals in Egypt and 
bordering countries. 
Animal 
Species 
Count. Area n 
n Pos 
[%] 
Diagnostic 
Method 
Study Design Ref. 
Sample 
collection 
(year) 
Buffaloes Egypt 
Giza, Cairo, 
Fayoum 
45 0  [0] 
IDEXX ELISA, 
Switzerland 
n. a. [133] 2012* 
  Egypt 
Muneeb abattoir, 
central Egypt 
153 6  [4] 
IDEXX ELISA, 
Westbrook, 
Maine 
n. a., domestic and imported livestock 
for slaughter 
[305] 2009 
 Egypt Sharkia, Cairo 40 3 [8] CFT n. a. [326] 1975-1976 
                  
Camels Egypt 
Muneeb abattoir, 
central Egypt 
10 7  [70] 
IDEXX ELISA, 
Westbrook, 
Maine 
n. a., domestic and imported livestock 
for slaughter 
[305] 2009 
  Egypt 
different districts 
North Sinai 
30 4  [13] indirect IFA 
n. a., animals from the patients' 
vicinity  
[142] 2006 
  Chad 
Chari-Baguirmi, 
Kanem 
142 114  [80] 
IDEXX ELISA, 
Switzerland 
livestock of the nomadic pastoralists [139] 1999-2000 
 Egypt Sharkia, Cairo 54 3 [6] CFT n. a. [326] 1975-1976 
 Sudan Central Sudan 110 16 [15] 
capillary 
agglutination 
test 
n. a., slaughter animals in Tamboul 
and camels in Butana plains to the 
northeast of Khartoum  
[327] 1987* 
                  
Cattle Egypt 
Dakahlia, 
Damietta, Port 
Said 
1,194 158  [13] 
IDEXX ELISA, 
Switzerland 
n. a., 9 farms, 4 farms with ≥500 and 
5 farms with ≤200 Holstein Friesian 
dairy cows 
[304] 2014* 
  Egypt 
Giza, Cairo, 
Fayoum 
54 7  [13] 
IDEXX ELISA, 
Switzerland 
n. a. [133] 2012* 
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  Egypt 
Muneeb abattoir, 
central Egypt 
161 0  [0] 
IDEXX ELISA, 
Westbrook, 
Maine 
n. a., domestic and imported livestock 
for slaughter 
[305] 2009 
 Egypt Sharkia, Cairo 352 11 [3] CFT n. a. [326] 1975-1976 
  Chad 
Southeastern 
shore of Lake 
Chad 
561 44  [8] 
ID Screen 
multi-species 
ELISA 
n. a., 4 islands [328] 2014* 
  Chad 
Chari-Baguirmi, 
Kanem 
195 8  [4] 
IDEXX ELISA, 
Switzerland 
livestock of the nomadic pastoralists [139] 1999-2000 
 Sudan South Sudan 52 21 [40] MAT 
n. a., 9 villages, region of Melut, 
Upper Nile province 
[329] 1983 
                  
Goats Egypt 
Giza, Cairo, 
Fayoum 
30 7  [23] 
IDEXX ELISA, 
Switzerland 
n. a. [133] 2012* 
  Egypt 
different districts 
North Sinai 
71 12  [17] indirect IFA 
n. a., animals from the patients' 
vicinity  
[142] 2006 
  Chad 
Chari-Baguirmi, 
Kanem 
134 18  [13] 
IDEXX ELISA, 
Switzerland 
livestock of the nomadic pastoralists [139] 1999-2000 
  Sudan 8 states 460 109  [24] 
Lisvet ELISA, 
Nouzilly, 
France 
selection of locations being main 
potential areas for livestock rearing, 
sampling of at least 4 groups 
[144] 2011 
 Sudan South Sudan 42 22 [53] MAT 
n. a., 9 villages, region of Melut, 
Upper Nile province 
[329] 1983 
                  
Sheep Egypt 
Giza, Cairo, 
Fayoum 
55 18  [33] 
IDEXX ELISA, 
Switzerland 
n. a. [133] 2012* 
  Egypt 
Muneeb abattoir, 
central Egypt 
174 14  [8] 
IDEXX ELISA, 
Westbrook, 
Maine 
n. a., domestic and imported livestock 
for slaughter 
[305] 2009 
  Egypt 
different districts 
North Sinai 
89 20  [23] indirect IFA 
n. a., animals from the patients' 
vicinity  
[142] 2006 
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 Egypt Sharkia, Cairo 49 1 [2] CFT n. a. [326] 1975-1976 
  Chad 
Chari-Baguirmi, 
Kanem 
142 16  [11] 
IDEXX ELISA, 
Switzerland 
livestock of the nomadic pastoralists [139] 1999-2000 
 Sudan South Sudan 32 20 [63] MAT 
n. a., 9 villages, region of Melut, 
Upper Nile province 
[329] 1983 
                  
Humans Egypt 
Giza, Cairo, 
Fayoum 
92 15  [16] 
Vircell ELISA, 
Granada, Spain 
n. a., veterinarians, veterinary 
workers and farmers from agricultural 
and urban districts 
[133] 2012* 
  Egypt 
different districts 
North Sinai 
180 9  [5] indirect IFA 
n. a., patients with FUO and healthy 
humans 
[142] 2006 
 Egypt 
Kafr Ayoub, 
Sharkia 
883 285 [32] EIA 
Proportional clustering strategy to 
select sample households randomly 
[330] 1991 
  Egypt Nile river delta 418 93  [22] EIA 
n. a., schoolchildren (8-14 years) 
from 4 schools in 3 villages 
[141] 1989 
 Egypt 
Nile Delta, Nile 
Valley, Suez 
Canal 
1286 192 [15] EIA/IFA 
n. a., serum from past projects in 
northeast Africa 
[138]** 1983-1989 
 Egypt Cairo 100 8 [8] MAT, CFT 
n. a., serum pairs (maternal and cord 
serum), most patients of the 
University Cairo Hospital were from 
rural, low income areas next to Cairo 
[331] 1966 
 Egypt Western Desert 572 45 [8] CFT 
n. a., Arab Bedouin tribes, 
cooperation varied between the areas 
sampled 
[332] 1962 
 Egypt 18 locations 1.271 232 [18] CFT 
Spot sampling of various 
communities 
[333]** 1959* 
  Chad 
Chari-Baguirmi, 
Kanem 
368 4  [1] 
IDEXX ELISA, 
Switzerland 
3 nomadic communities: Fulani cattle 
breeders, Arab camel and cattle 
breeders 
[139] 1999-2000 
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 Sudan North Sudan 371 199 [54] EIA/IFA 
n. a., 2 locations (Merowie, Karima), 
samples from past projects in 
northeast Africa 
[138]** 1983-1989 
 Sudan 1 village 73 19 [26] CFT 
One Nilotic tribe (the Shilluk) in the 
village Akwajo-Pakwanythtor 
[334] 1961-1962 
 Sudan 
11 locations in 
the South 
401 28 [7] CFT 
Spot sampling of various 
communities 
[333]** 1959* 
Count. = Country, n = number of individuals tested, n. a. = not available, Pos = positive, Ref. = reference; 
CFT = complement fixation test, EIA = enzyme immunoassay, ELISA = enzyme linked immunosorbent assay, IFA = immunofluorescence 
assay, MAT = microagglutination test; 
*year published, no data available on period of sample collection 
**Not all results listed. 
No data are available for Libya.  
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Figure A1. Verification of the efficiency of the IDEXX conjugated anti-ruminant 
antibody to detect antibodies in serum samples of camelidae. 
An empty 96-well plate was coated with coating-buffer in-house to detect animal 
species specific antibodies. Further steps were performed as described in the 
manufacturer`s instruction (IDEXX). Serum samples of a seropositive cow and different 
camelidae and control groups (donkey, dog) were used. Various dilution ratios were 
performed to find the best ratio for camel serum samples (1:1,000). Pictures were taken 
briefly before the reaction was stopped (blue) and after stopping (yellow). 
 
  
Cattle 
Alpaca 
Llama 
Camel 
Donkey 
Dog 
1:100            1:500           1:1,000        1:2,000         1:5,000        1:10,000 
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Donkey 
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Figure A2. Distribution of the OD values obtained from cattle. 
The figures A2-A6 show the distribution of the OD values obtained from the ELISAs of 
each animal species to assess cutoff values. The OD results include two peaks: 1. before 
the negative and 2. after the positive cutoff. Given cutoff values for the ELISA used 
(IDEXX, Switzerland) determine <30% to be negative and ≥40% to be positive. 
Figure A2 shows a diagram of the obtained ELISA results of cattle. 
n = number, OD = optical density 
 
Figure A3. Distribution of the OD values obtained from buffaloes. 
n = number, OD = optical density 
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Figure A4. Distribution of the OD values obtained from sheep. 
n = number, OD = optical density 
 
 
Figure A5. Distribution of the OD values obtained from goats. 
n = number, OD = optical density 
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Figure A6. Distribution of the OD values obtained from camels. 
n = number, OD = optical density 
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Figure A7. Seroprevalence in Egypt for cattle and buffaloes. 
The maps of Egypt show the seroprevalence of Coxiella burnetii-specific antibodies for each animal species and in total. The green dots show the 
position of each randomly selected sampling site in each governorate. The sampling site ‘Halayeb’, highlighted by a brown dot, is located in the 
territory disputed between Egypt and Sudan.  
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Figure A8. Seroprevalence in Egypt for sheep and goats. 
The green dots show the position of each randomly selected sampling site in each governorate. The sampling site ‘Halayeb’, highlighted by a brown 
dot, is located in the territory disputed between Egypt and Sudan. 
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Figure A9. Seroprevalence in Egypt for camels and in total. 
The green dots show the position of each randomly selected sampling site in each governorate. The sampling site ‘Halayeb’, highlighted by a brown 
dot, is located in the territory disputed between Egypt and Sudan. 
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